You are here

spacer

Commercialization Assistance Program (CAP)

For Phase II SBIR & STTR Awardees

Commercialization Assistance Program (CAP) Logo

CAP - Personalized Assistance • Knowledge Transfer • Business Outcomes

What is the Commercialization Assistance Program (CAP)?

Today's dynamic marketplace in the human life sciences and healthcare requires that companies focus on identifying and connecting with key customers, articulate the highest and best use of their innovative solutions and build sustainable pathways to revenue and continuing relevance.

With these in mind, the NIH Commercialization Assistance Program (CAP), offered annually since 2004, is designed to help some of the agency’s most promising small life science and healthcare Phase II grantees develop their commercial businesses and transition their SBIR/STTR-funded technologies into the marketplace. Applicants are selected via a competitive process for a limited number of slots in the program.

Funded by NIH and managed through a contract with Larta, Inc. (www.larta.org) of Los Angeles, CA, the CAP provides selected participants with individualized assistance toward accomplishing key commercialization goals. This is achieved through individual mentoring and consulting sessions, training workshops, access to domain experts and focus on outcomes that will enhance the commercialization profile and readiness of participating grantees. Please take a look at an overview of historic CAP outcomes.

Applications are now open and the deadline is September 2, 2014. All applications will be competitively reviewed, and participants will be notified on or about September 15, 2014. This year we expect to accept 80 companies into the program. The assistance through CAP begins in September 2014 and spans nine (9) months, ending in June 2015.

Who is Eligible to Participate?

  • Companies whose NIH SBIR and STTR Phase II, Phase IIB or Phase II portion of Fast-track award is or was active in the past 5 fiscal years. Projects that ended before August 2009 are not eligible. Awardees from the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) can also apply.
  • Companies that meet the current SBIR/STTR small business eligibility criteria as described in the NIH SBIR/STTR Omnibus solicitation. The solicitation and its parent funding opportunity announcements are available from the NIH Small Business Funding Opportunities website.
  • Previous NIH CAP participants with a different Phase II award that participated no more than two (2) times before. Please note that first time applicants to the CAP will be given priority due to the limited number of slots.

Is CAP Right for You?

The NIH CAP offers opportunities to both "emerging companies," i.e. new to, or with limited experience in the commercial marketplace, and “seasoned companies” with more established commercialization experience who are facing more complex business strategic challenges. The program is customized to meet the needs of emerging and seasoned companies in three distinct tracks, each different in its objectives and outcomes: The Commercialization Training Track (CTT) for emerging companies, the Accelerated Commercialization Track (ACT), and the Regulatory Training Track (RTT). The CAP’s eighty (80) available slots will be distributed between the three tracks:

  • Commercialization Training Track (CTT) - This track will apply to the majority of the SBIR/STTR Phase II companies. It is aimed at assisting participants with evaluating their commercialization options based on their specific technologies (including the need and prospect for investment, strategic partnerships or licensing) and to develop a solid market-entry plan (“Commercialization Roadmap”) covering an 18-month period. It also assists participants in the development of market-appropriate tools to accomplish these objectives, and provides opportunities for direct industry feedback in live session. Participants work one-on-one with a principal advisor and industry experts as needed.
  • Accelerated Commercialization Track (ACT) - This track will apply to a selected group of the SBIR-STTR- funded companies who have successfully commercialized products and/or services, generated revenue, established partnerships and/or otherwise achieved a level of market development that is sustainable over a definitive period. However, they may need to address a specific applicable issue (such as a license-focused IP strategy or a term sheet for investors) whose resolution is key to their continued growth. This track specifically deploys domain experts to help participants achieve these outcomes.
  • Regulatory Training Track (RTT) – This track will apply to a selected group of the SBIR-STTR-funded companies whose technologies require regulation by the Food and Drug Administration (FDA). These companies are either preparing for initial engagement with and submission to the FDA or have already done so but may need to address specific applicable issues related to their application, developing a solid regulatory plan or addressing feedback from the FDA in order to move their technology development along toward achieving regulatory milestones and approval. This track specifically deploys regulatory business experts to help participants achieve these outcomes.

How Much Time Does CAP Require?

The commitment of time and resources with management support is vital. Company CEO participation is highly encouraged and expected in this program. Past experience indicates that the best results are achieved when the CEO serves as the company’s CAP leader and is actively involved. Hence, successful applicants will be those where top management – founder, CEO, or other key management member designated by the CEO leading commercialization efforts at the company are directly involved in the program.

The CAP is a 9-month long program. However, it is not a curriculum-based program and should not be perceived as continuous 9 months of engagement. The CEO or designated representative will set their monthly schedule with assigned principal adviser depending on the nature of the work performed in the CAP. Majority of the interactions occur virtually via phone calls or webinars, except for the required in-person Kickoff and Industry Feedback workshops. There will be a few specific deliverables expected of the company, which are envisioned to serve as tools to ensure progress of work toward a meaningful and actionable outcome within the time allotted.

CAP participation is free of charge for selected participating companies; however, participants in all tracks are responsible for travel and lodging expenses associated with attending the mandatory Commercialization Training Workshop (CTW) and, in the case of CTT track participants, for one Industry Feedback Session.

NOTE: NIH will not provide additional funding covering your participation in CAP; however, participants with a current active Phase II SBIR or STTR award may re-budget funds within the total costs awarded, to cover allowable travel expenses for CAP events without NIH prior approval unless the re-budgeting action constitutes a change in scope or if the terms of award prohibit the use of funds for this purpose. Selected companies are encouraged to contact their funding NIH institute program officer for inquires in this regard.

The CAP in Detail

As already mentioned, the CAP is a three-track program customized to serve the needs of companies at different levels of commercialization experience and expertise.

 

Commercialization Training Track (CTT)

The Commercialization Training Track (CTT) applies to the majority of the SBIR and STTR Phase II companies. CTT is aimed at assisting participants with understanding their customer, evaluating their commercialization options based on their specific technologies (including the need and prospect for investment, strategic partnerships or licensing) and to develop a solid market-entry Commercialization Roadmap (a strategic action plan) covering an 18-month period, and provides opportunities for live industry feedback in a live session. It also assists participants in the development of market-appropriate tools to accomplish these objectives.

Over a 9-month period, each CTT participant will:

CAP Timeline CTT Companies

CAP Timeline CTT Companies

By the completion of the program, each participant should have a solid understanding of who their customer is, what the commercial value of their technology is, how it is positioned in the current market landscape, what the true competitive posture of the company is, and what gaps remain to be addressed. Each participant will have developed his or her own Management Toolkit which includes an 18-month Commercialization Roadmap (strategic action plan) that addresses concrete steps to be pursued, who is responsible for activities to be pursued, what the anticipated financial commitment will be, and what outcomes may be expected as a result of these activities.

Principal Advisor Assignments and Work Plan Development – September 2014 to November 2014

Upon selection as a CTT participant, a Principal Advisor (PA) is assigned to work closely with each participant and is matched with the company based on the advisor’s experience and expertise and the company’s needs. PAs are experienced consultants and business executives with recorded success in guiding innovative enterprises. Your PA operates as a facilitator and counselor, helping you to prepare materials as needed, and serving as a sounding board throughout the program as you develop an 18-month Commercialization Roadmap (your Strategic Action Plan). Participants work one-on-one with their PA on a regular monthly basis, and other investment and/or industry advisors/experts will be consulted when warranted. Advisors will not do the work for you, but will mentor, guide, and assist. All participants will be coached and mentored via face-to-face meetings and via remote communication tools, e.g., phone, email, Internet.

Your first communications with your PA will focus on your commercialization status and knowledge and will help a program work plan that identifies obstacles and hurdles you face (or are likely to face) and broad outlines of solutions available to you. This plan is referred to as the CAP Planning/Assessment Template ("Template") and will be completed at the onset of the program to guide your work through the program. The Template will help identify gaps in operations, systems, technology product development, etc. and will be useful in defining the optimal path to market and commercialization. It is also used to align with the steps participants need to take to resolve the gaps, and thus to develop an 18-month Commercialization Roadmap (strategic action plan).

During this phase of the CAP, you and your PA will also prepare for your face-to-face meeting at the program’s Commercialization Training Workshop, to take place in November 2014.

Commercialization Training Workshop – November 10-11, 2014, Los Angeles, CA

(The CEO or other top management team member(s) with oversight and authority over commercialization issues is strongly encouraged to attend.)

All participants, in all tracks (CTT, ACT, RTT) are required to attend the Commercialization Training Workshop (CTW). All participants are responsible for travel and lodging expenses associated with attending this mandatory event. This workshop offers in-depth interactive seminars led by advisors and experts from the legal, investment, and industry communities. Three major components of the CTW are: a face-to-face meeting and work session between you and your assigned PA; interactive sessions comprised of program introduction/orientation and commercialization topics; and company networking. The CTW also provides excellent opportunities to network with fellow CAP participants, other key people associated with the program, industry experts in attendance and NIH staff.

November 10, 2014

The program will kick off with welcome remarks and overview from NIH program staff and introductions to key CAP team members to be followed by a series of interactive seminars led by industry experts:

Agenda topics may include but are not restricted to:

  • Financing and Funding Issues for Life Science Companies
  • Partnering/Investment Planning
  • Intellectual Property Management
  • Early Stage Branding and Marketing Issues and Concerns (including social media)
  • Healthcare IT Commercialization Issues (for those companies in the Healthcare/IT field)
  • Regulatory and Reimbursement Issues

November 11, 2014

Face-to-Face Meeting with your Principal Advisor - A 1-hour face-to-face meeting with your PA will be scheduled on the first day of the workshop. It will be a continuation of your September/October discussions with your PA and will include an in-depth discussion of the company’s status, commercialization needs, and the work plan (Planning/Assessment Template). Participants will also discuss various elements of the program including program resources and the program’s management toolkit. At the end of this meeting, you should have a clear understanding of all program details, a customized commercialization approach, and a firm commitment from you as the participant to invest the required time and effort to the CAP.

Company Exhibits and Networking – You and fellow CAP participants will have an opportunity to network throughout the day in the exhibit hall where companies’ posters will be featured. An online Meeting Scheduler will also be available to allow you and other event attendees to schedule private meetings among yourselves and others in attendance at the CTW.

Business and Strategic Planning and Development of Management Toolkit –

September 2014 through June 2015

After the CTW, companies and PAs start working on the work plan agreed upon and the development of the Management Toolkit, which will include materials useful for implementing their commercialization plan both during and after the program ends. While the Toolkit will be customized for each participant’s needs, it will include information relevant to the following components:

  • 18-Month Commercialization Roadmap (also referred to as the Roadmap or strategic action plan): At the end of the program, each company will have a list of strategies, tasks and milestones with a timeline looking forward over the next 18 months. Ideally, this would include budgets necessary to accomplish the necessary tasks, and may be broken down by specific periods over the course of the 18 months covered by the Roadmap. This tool will be useful in managing and tracking your commercialization progress and outcomes after the CAP.
  • Road Show Presentation: This is a short PowerPoint presentation to "pitch" the company to potential investors, strategic partners, licensees or customers. It will provide a brief, informative and compelling glimpse of the company, to attract the interest of a targeted audience at private meetings or at pitch events such as investment forums, conferences, or trade shows. (Note: This is not intended to serve as preparation for a specific event nominated by CTT participants, nor is there a commitment to assisting with this task for that purpose.)
Quad Chart/Virtual Showcase and Keywords – February 2015

Each company will develop a quad chart that can be used for showcasing and promoting the company’s technology assets, including on NIH’s Web site and portal. Each chart will include: (1) specific company information, (2) your management team, (3) an overview of your technology and its competitive advantage(s), and (4) your company’s pipeline of products under development or a detailed description of the technology.

Feedback Sessions – February and March 2015

Feedback Sessions are face-to-face, private (closed door) working meetings for the participant to present its Commercialization Roadmap (18-month Strategic Action Plan) to a group of external mentors and industry experts who will provide constructive feedback. CTT participants are expected to attend. (See previous note regarding travel costs.)

These outside experts will provide objective and frank feedback on the company’s commercialization opportunity and strategy (as presented) with fresh perspectives and, perhaps, suggestions and options other than those presented in both oral and written formats. At the end of the session, Larta will compile the written feedback collected from each external mentor/expert, and provide the participant with an Attendee Scorecard reflecting their critique, rating and recommendations on the participant’s presentation content, commercialization strategy, timeline, milestones, and other factors. You will have the opportunity to adjust and amend materials in your Management Toolkit based on the advice and recommendations provided. In addition, you will have the unparalleled opportunity to meet and network with industry experts, thus providing you contacts for future reference. Feedback Sessions are widely considered to be a major highlight and distinguishing feature of NIH’s CAP.

Feedback Sessions are designed to be as convenient as possible for participating companies, and also to cultivate networking. Participants need attend only one day at any one location of the following three Feedback Sessions:

  • Los Angeles, CA February 23-24, 2015
  • Washington, DC March 2-3, 2015

Dates are tentative and may change due to unforeseen circumstances. Participants will be informed in a timely fashion should any changes occur.

Following the Feedback Sessions, participants will continue to work with their PAs on refining their strategies, action plans, presentations, and other Management Toolkit documents. If there is a need for other advisors from a particular specialty area, e.g. legal, regulatory, etc., such expertise may be brought in during this period as well.

Close-out Web Meetings – June 2015

A Close-out Web Meeting is the final CAP event. This is an opportunity for the participant to provide NIH program managers, your Principal Advisor and key program staff a “live” look at the company’s progress at the end of the program. The primary focus of this event is for you to present to NIH SBIR/STTR program managers the feedback received from the Feedback Sessions, what you and your company has accomplished since the Feedback Sessions, your 18-month Action Plan (next steps/goals), and your plan to achieve the milestones set out in the Plan. The meeting is informal, similar to the monthly teleconferences with the Principal Advisor, and will last approximately 30 minutes. This session will be conducted over the Web, and a presentation will be shared with attendees.

Program Feedback and Tracking – During and at the completion of the program

In order to ensure quality control and to enable NIH to evaluate the program’s impact on participants’ commercialization efforts and outcomes, tracking of your commercialization progress will be on-going throughout the program. We will collect data from you at pre-designated points of the program (Application Form, CAP Assessment Template, Feedback Sessions Scorecards, and Monthly Reports). The data will be condensed and presented on the Program Portal via a ”Company Snapshot”. Both you and the PA will have the capability to enter any update at any time in the Portal and these will be reflected automatically in the Company Snapshot.

Additionally, formal surveys and feedback will be solicited at the outset and at the conclusion of the program. The data from the feedback will allow NIH to assess the program and its implementation, and the tracking will keep NIH informed of the progress your company has made with commercializing the NIH SBIR/STTR-developed product.

 

Accelerated Commercialization Track (ACT)

The Accelerated Commercialization Track (ACT) of the NIH-CAP applies to a select group of SBIR-STTR-funded companies who have successfully commercialized products and/or services, generated revenue, established partnerships and/or otherwise achieved a level of market development that is sustainable over a definitive period.

However, with respect to the particular technology, product or service under which they have enrolled in CAP, they may need to address a specific applicable barrier or issue, as follows, but not limited to:

  • Financial Issues and Valuation (Financial model, budget analysis)
  • Intellectual Property (license-focused IP strategy, refresh of patent portfolio)
  • Market Strategy (related to a specific customer or opportunity)
  • Marketing/Branding (Marketing materials, branding/website)
  • Strategic Partnering (Investor/Go To Market Presentation, Term Sheet for investor/partnership)

The resolution of these issues or barriers may be the key to their continued growth. This track uses industry experts (called “expert resources”) to help participants achieve these outcomes. 15 slots are available for the Accelerated Commercialization Track.

During the program, each ACT participant will:

CAP Timeline ACT Companies

CAP Timeline ACT Companies

The following are the key identifiable phases of the ACT track, in sequence.

Principal Advisor Assignments and Outcome Proposal Development – September to November 2014

Upon selection as an ACT participant, a Principal Advisor (PA) is assigned to work closely with each participant and is matched with the company based on the advisor’s experience and expertise and the company’s needs. Your PA operates as a facilitator and counselor, helping you to prepare materials as needed, and serving as a sounding board throughout the program as you develop, and work towards the achievement of, a Targeted Outcome for the CAP. Participants work one-on-one with their PA on a regular monthly basis. The PAs are experienced consultants and business executives with recorded success in guiding innovative enterprises. Advisors will not do the work for you, but will mentor, guide, assist and generate strategic connections for you. All participants will be coached and mentored via face-to-face meetings and/or via remote communication tools, e.g., phone, email, Internet.

Your first communications with your PA will focus on the development of an "Outcome Proposal." The parties will discuss the companies’ most critical commercialization issues in order to focus on developing a "Targeted Outcome" to be accomplished during the program. Targeted outcomes may include, but are not limited to, addressing regulatory issues, legal and/or financial structuring/restructuring, management recruitment, term-sheet development, product or prototype design or other issues. Whether a specific outcome is appropriate for the company is determined in discussions between the PA and the Company. A single targeted outcome will become a part of an Outcome Proposal which will discuss the participant’s proposed approach to achieve the targeted outcome. The Proposal will spell out clearly the most critical issues pertinent to creating a desired solid commercialization outcome, what the targeted outcome will be (e.g. a "regulatory guidance" document, a design, a recruit), the best path of resolution within a timeline consistent with the duration of the program, and any “expert resources” who may be needed to achieve the targeted outcome. NIH must approve this Outcome Proposal before moving forward in the program.

During this phase of the CAP, you and your PA will also prepare for your face-to-face meeting at the program’s Commercialization Training Workshop, to take place in November, 2014.

Commercialization Training Workshop – November 10-11, 2014, Los Angeles, CA

(The CEO or other top management team member(s) with oversight and authority over commercialization issues is strongly encouraged to attend.)

All participants, in all tracks (CTT, ACT, RTT) are required to attend the Commercialization Training Workshop (CTW). All participants are responsible for travel and lodging expenses associated with attending this mandatory event. This workshop offers in-depth interactive seminars led by advisors and experts from the legal, investment, and industry communities. Three major components of the CTW are: a face-to-face meeting and work session between you and your assigned PA; interactive sessions comprised of program introduction/orientation and commercialization topics; and company networking. The CTW also provides excellent opportunities to network with fellow CAP participants, other key people associated with the program, industry experts in attendance and NIH staff.

November 10, 2014

The program will kick off with welcome remarks and overview from NIH program staff and introductions to key CAP team members to be followed by a series of interactive seminars led by industry experts:

Agenda topics may include but are not restricted to:

  • Financing and Funding Issues for Life Science Companies
  • Partnering/Investment Planning
  • Intellectual Property Management
  • Early Stage Branding and Marketing Issues and Concerns (including social media)
  • Healthcare IT Commercialization Issues (for those companies in the Healthcare/IT field)
  • Regulatory and Reimbursement Issues

November 11, 2014

Face-to-Face Meeting with your Principal Advisor - A 1-hour face-to-face meeting with your PA will be scheduled on the first day of the workshop. It will be a continuation of your September/October discussions with your PA and will include an in-depth discussion of the company’s status, commercialization needs, and the work plan (Planning/Assessment Template). Participants will also discuss various elements of the program including program resources and the program’s management toolkit. At the end of this meeting, you should have a clear understanding of all program details, a customized commercialization approach, and a firm commitment from you as the participant to invest the required time and effort to the CAP.

Company Networking – You and fellow CAP participants will have an opportunity to network throughout the day. An online Meeting Scheduler will also be available to allow you and other event attendees to schedule private meetings among yourselves and others in attendance at the CTW.

Transaction-Oriented Work Plan – November 2014 through Completion

After the CTW, companies and PAs start working on the work plan agreed upon and the development of the Outcome Proposal. Upon NIH approval of the Outcome Proposal, the participant will work with his/her PA to complete the transaction-oriented work plan. The work plan should clearly indicate a specific need and a clear path to accomplish a tangible outcome and will include a timeline with specific milestones, and an estimated date for completion. The plan should be capable of being accomplished within the duration of the program.

ACT companies will also receive assistance from Expert Resources (ER), who are professionals identified jointly by each ACT company and its PA as critical to the achievement of the targeted outcome. ERs are experts in critical aspects of commercialization, such as intellectual property, accounting, management recruiting, government procurement, etc. The assistance provided by the PAs and ERs during the course of the CAP is fully covered by the NIH SBIR/ STTR Office; participants should use these resources only for the length and scope directed by the program. However, participants are free to negotiate contingency arrangements with a provider of services of their choice for work that may endure beyond the CAP, covered by their own financial resources.

In addition to achieving the approved outcome, the company will work with their PA to develop an 18-Month Commercialization Roadmap (also referred to as the Roadmap or strategic action plan). At the end of the program, each company will have a list of strategies, tasks and milestones with a timeline looking forward over the next 18 months in relation to their achieved Outcome. Ideally, this would include budgets necessary to accomplish the necessary tasks, and may be broken down by specific periods over the course of the 18 months covered by the Roadmap. This tool will be useful in managing and tracking your commercialization progress and outcomes after the CAP.

* Disclaimer: NIH does not endorse the expert resources/advisors for the purpose of retaining them for any purpose following the conclusion of the program. Any arrangement with such resources/advisors beyond the service rendered under the program is the responsibility of the CAP participating Company ONLY.

Quad Chart/Virtual Showcase and Keywords – February 2014

Each company will develop a quad chart that can be used for showcasing and promoting the company’s technology assets, including on NIH’s Web site and portal. Each chart will include: (1) specific company information, (2) your management team, (3) an overview of your technology and its competitive advantage(s), and (4) your company’s pipeline of products under development or a detailed description of the technology.

Final Outcome Report – Near completion of the program

Working with the company, the PA will prepare a Final Outcome Report that documents the participant’s progress and end-results with meeting the company’s desired outcome. It will address whether the timeline and work plan were adhered to throughout the program and if the desired outcome was accomplished. In cases where the desired outcome is not reached, the Final Outcome Report will specify the key issues that prevented the outcome from occurring and the company’s next steps towards achieving the targeted outcome.

Close-out Web Meetings – March through April 2014

A Close-out Web Meeting is the final CAP event. This is an opportunity for the participant to provide NIH program managers, your Principal Advisor and key program staff a “live” look at the company’s progress at the end of the program. The primary focus of this event is for you to present to NIH SBIR/STTR program managers what your company has accomplished on the targeted outcome, your Transaction-Oriented Work Plan, and your strategy to achieve the milestones set out in the Work Plan. The meeting is informal, similar to the monthly teleconferences with the Principal Advisor, and will last approximately 30 minutes. A Web tool will be used to facilitate the sharing of the documents being discussed

Program Feedback and Tracking – During and at the completion of the program

In order to ensure quality control and to enable NIH to evaluate the program’s impact on participants’ commercialization efforts and outcomes, tracking of your commercialization progress will be on-going throughout the program. We will collect data from you at pre-designated points of the program (Application Form, CAP Assessment Template, Outcome Proposal, Final Report, and Monthly Reports). The data will be condensed and presented on the Program Portal via Company Snapshot. Both you and the PA will have the capability to enter any update at any time in the Portal and these will be reflected automatically in the Company Snapshot.

Additionally, formal surveys and feedback will be solicited at the outset and at the conclusion of the program. The data from the feedback will allow NIH to assess the program and its implementation, and the tracking will keep NIH informed of the progress your company has made with commercializing the NIH SBIR/STTR-developed product.

 

Regulatory Training Track (RTT)

The Regulatory Training Track (RTT) of the NIH-CAP will apply to a selected group of NIH-funded companies whose technologies require regulation by the Food and Drug Administration (FDA). These companies are either preparing for initial engagement with and submission to the FDA or have already done so but may need to address specific applicable issues related to their application, developing a solid regulatory plan or addressing feedback from the FDA in order to move their technology development along toward achieving regulatory milestones and approval. This track specifically deploys regulatory business experts to help participants achieve these outcomes.

With the assistance of the advisor/mentor, a work plan will be documented describing the participant’s single most critical and desired outcome that is deemed to be possible during the program that relates to the Food and Drug Administration (FDA) approval process.

Assistance provided by the advisor/ mentor may include but are not limited to:

  • Identification of the company’s goals for its product – based on discussion with the company, the advisor/ mentor will assess what is the company’s expected product, its intended use and indications for use.
  • Identification of the regulatory path –based on the company’s goal(s), the advisor/ mentor will recommend a specific regulatory path that should be taken. This will be applicable also to companies that have previously submitted materials to the FDA, received rejection or otherwise encountered challenges with their path to submission or approval.
  • Development of regulatory strategy – the advisor/ mentor will work with the company to address regulatory hurdles the company will likely face given its product, the regulatory path and the company’s current approach to navigating the regulatory landscape.
  • Assessment of the success of the chosen regulatory path- the Contractor shall devise metrics to be used for assessment for the likelihood of the success of the recommended regulatory path.

During the program, each RTT participant will:

CAP Timeline RTT Companies

CAP Timeline RTT Companies

The following are the key identifiable phases of the RTT track, in sequence.

Principal Advisor Assignments and Outcome Proposal Development – September through November 2014

Upon selection as an RTT participant, a Principal Advisor (PA) is assigned to work closely with each participant and is matched with the company based on the advisor’s experience and expertise and the company’s needs. Your PA operates as a facilitator and counselor, helping you to prepare materials as needed, and serving as a sounding board throughout the program as you develop, and work towards the achievement of, a Targeted Outcome for the CAP. Participants work one-on-one with their PA on a regular monthly basis. The PAs are experienced consultants and business executives with recorded success in guiding innovative enterprises. Advisors will not do the work for you, but will mentor, guide, assist and generate strategic connections for you. All participants will be coached and mentored via face-to-face meetings and/or via remote communication tools, e.g., phone, email, Internet.

Your first communications with your PA will focus on the development of an "Outcome Proposal". The parties will discuss the companies' most critical commercialization issues in order to focus on developing a "Targeted Outcome" to be accomplished during the program. Targeted outcomes may include, but are not limited to, addressing regulatory issues, language for indication for use, optimal regulatory or reimbursement pathway, or identify reimbursement code for different payors, etc. Whether a specific outcome is appropriate for the company is determined in discussions between the PA and the Company. A single targeted outcome will become a part of an Outcome Proposal which will discuss the participant’s proposed approach to achieve the targeted outcome. The Proposal will spell out clearly the most critical issues pertinent to creating a desired solid commercialization outcome, what the targeted outcome will be (e.g. a "regulatory guidance" document, indication for use, reimbursement code, etc.), the best path of resolution within a timeline consistent with the duration of the program, and any “expert resources” who may be needed to achieve the targeted outcome. NIH must approve this Outcome Proposal before moving forward in the program.

During this phase of the CAP, you and your PA will also prepare for your face-to-face meeting at the program's Commercialization Training Workshop, to take place in November 2014.

Commercialization Training Workshop – November 10-11, 2014, Los Angeles, CA

(The CEO or other top management team member(s) with oversight and authority over commercialization issues is strongly encouraged to attend.)

All participants (CTT, ACT, RTT) are required to attend the Commercialization Training Workshop (CTW). All participants are responsible for travel and lodging expenses associated with attending this mandatory event. This workshop offers in-depth interactive seminars led by advisors and experts from the legal, investment, and industry communities. Three major components to the CTW: a face-to-face meeting between you and your assigned PA; interactive seminar comprised of program introduction/orientation and commercialization topics; and company exhibits and networking. The CTW also provides excellent opportunities to network with fellow CAP participants, other key people associated with the program, industry experts in attendance and NIH staff.

All participants, in all tracks (CTT, ACT, RTT) are required to attend the Commercialization Training Workshop (CTW). All participants are responsible for travel and lodging expenses associated with attending this mandatory event. This workshop offers in-depth interactive seminars led by advisors and experts from the legal, investment, and industry communities. Three major components of the CTW are: a face-to-face meeting and work session between you and your assigned PA; interactive sessions comprised of program introduction/orientation and commercialization topics; and company networking. The CTW also provides excellent opportunities to network with fellow CAP participants, other key people associated with the program, industry experts in attendance and NIH staff.

November 10, 2014

The program will kick off with welcome remarks and overview from NIH program staff and introductions to key CAP team members to be followed a series of interactive seminars led by industry experts:

Agenda topics may include but are not restricted to:

  • Financing and Funding Issues for Life Science Companies
  • Partnering/Investment Planning
  • Intellectual Property Management
  • Early Stage Branding and Marketing Issues and Concerns (including social media)
  • Healthcare IT Commercialization Issues (for those companies in the Healthcare/IT field)
  • Regulatory and Reimbursement Issues

November 11, 2014

Face-to-Face Meeting with your Principal Advisor - A 1-hour face-to-face meeting with your PA will be scheduled on the first day of the workshop. It will be a continuation of your September/October discussions with your PA and will include an in-depth discussion of the company’s status, commercialization needs, and the work plan (Planning/Assessment Template). Participants will also discuss various elements of the program including program resources and the program’s management toolkit. At the end of this meeting, you should have a clear understanding of all program details, a customized commercialization approach, and a firm commitment from you as the participant to invest the required time and effort to the CAP.

Company Exhibits and Networking – You and fellow CAP participants will have an opportunity to network throughout the day in the exhibit hall where companies' posters will be featured. An online Meeting Scheduler will also be available to allow you and other event attendees to schedule private meetings among yourselves and others in attendance at the CTW.

Transaction-Oriented Work Plan – September 2014 through Completion

Upon NIH approval of the Outcome Proposal, the participant will work with his/her PA to complete the transaction-oriented work plan. The work plan should clearly indicate a specific need and a clear path to accomplish a tangible outcome and will include a timeline with specific milestones, and an estimated date for completion. The plan should be capable of being accomplished within the duration of the program.

RTT companies will also receive assistance from Expert Resources (ER), who are professionals identified jointly by each RTT company and its PA as critical to the achievement of the targeted outcome. ERs are experts in critical aspects of commercialization, such as intellectual property, accounting, management recruiting, government procurement, etc. The assistance provided by the PAs and ERs during the course of the CAP is fully covered by the NIH; participants should use these resources only for the length and scope directed by the program. However, participants are free to negotiate contingency arrangements with a provider of services of their choice for work that may endure beyond the CAP, covered by their own financial resources.

In addition to achieving the approved outcome, the company will work with their PA to develop an 18-Month Commercialization Roadmap (also referred to as the Roadmap or strategic action plan). At the end of the program, each company will have a list of strategies, tasks and milestones with a timeline looking forward over the next 18 months in relation to their achieved Outcome. Ideally, this would include budgets necessary to accomplish the necessary tasks, and may be broken down by specific periods over the course of the 18 months covered by the Roadmap. This tool will be useful in managing and tracking your commercialization progress and outcomes after the CAP.

* Disclaimer: NIH does not endorse the expert resources/advisors for the purpose of retaining them for any purpose following the conclusion of the program. Any arrangement with such resources/advisors beyond the service rendered under the program is the responsibility of the CAP participating Company ONLY.

Quad Chart/Virtual Showcase and Keywords – February 2015

Each company will develop a quad chart that can be used for showcasing and promoting the company’s technology assets, including on NIH’s Web site and portal. Each chart will include: (1) specific company information, (2) your management team, (3) an overview of your technology and its competitive advantage(s), and (4) your company’s pipeline of products under development or a detailed description of the technology.

Final Outcome Report – Near completion of the program

Working with the company, the PA will prepare a Final Outcome Report that documents the participant’s progress and end-results with meeting the company’s desired outcome. It will address whether the timeline and work plan were adhered to throughout the program and if the desired outcome was accomplished. In cases where the desired outcome is not reached, the Final Outcome Report will specify the key issues that prevented the outcome from occurring and the company’s next steps towards achieving the targeted outcome.

Close-out Web Meetings – March through May 2014

A Close-out Web Meeting is the final CAP event. This is an opportunity for the participant to provide NIH program managers, your Principal Advisor and key program staff a “live” look at the company’s progress at the end of the program. The primary focus of this event is for you to present to NIH SBIR/STTR program managers what your company has accomplished on the targeted outcome, your Transaction-Oriented Work Plan, and your strategy to achieve the milestones set out in the Work Plan. The meeting is informal, similar to the monthly teleconferences with the Principal Advisor, and will last approximately 30 minutes. A Web tool will be used to facilitate the sharing of the documents being discussed.

Program Feedback and Tracking – During and at the completion of the program

Tracking of your commercialization progress will be on-going throughout the program. We will collect data from you at pre-designated points of the program (Application Form, CAP Assessment Template, Outcome Proposal, Final Report, and Monthly Reports). The data will be condensed and presented on the Program Portal via Company Snapshot. Both you and the PA will have the capability to enter any update at any time in the Portal and these will be reflected automatically in the Company Snapshot.

Additionally, formal surveys and feedback will be solicited at the outset and at the conclusion of the program. The data from the feedback will allow NIH to assess the program and its implementation, and the tracking will keep NIH informed of the progress your company has made with commercializing the NIH SBIR/STTR-developed product.

Contacts

NIH
Lenka Fedorkova, Ph.D.
CAP Manager
Assistant Manager SBIR/STTR Program Office
Office of Extramural Programs
National Institutes of Health
Ph: (301) 435-0921
sbir@od.nih.gov

Larta, Inc.
Judy Hsieh
Senior Program Manager
Larta, Inc.
Ph: (213) 538-1444
jhsieh@larta.org

About the Application

Application to the NIH CAP is done online, and should take less than one hour; once you log on to the application portal, detailed instructions will guide you through the process. Please note that access to the portal is secured behind a password protected firewall.

Submit your application

About the Selection Process

Reviews of completed applications will be conducted by a committee comprising NIH SBIR-STTR program managers and Larta Inc. staff who are directly involved with the CAP. All information in the application will be held in the strictest confidence. Pertinent information will be made available only to your assigned mentor ("Principal Advisor" or PA) after you have been selected and accepted our invitation to join the program.

Evaluation Criteria

The following criteria will be considered in the evaluation and selection of participants into the program. It is not necessary (or expected) that every item on these lists has been accomplished or achieved by the applicant. Understanding of and commitment to commercial and market development is important.

Commercialization Goals of Company:
  • Expression of clear commercial goals, achievement of previously set commercial goals, and strong likelihood of attaining commercial goals
  • Realistic assessment of the specific market for the technology, current competition and differentiation
  • Clear understanding of critical milestones in anticipation of commercial entry: e.g. need for outside funding, partnerships, regulatory approval, identification of additional team members, etc.
  • Progress to date in achieving commercial success e.g. raising capital, developing partnerships, product or service sales, licensing outcomes etc.
  • Experience of the team or the principal contact at the company
  • Understanding of, and/or experience working with, potential partners or investors
  • Knowledge of, and/or exposure to, commercialization objectives, process and outcomes. Expression of commercialization goals, both near- and long-term
  • Alignment of expressed goals with needs
Business Case Strength:
  • The intellectual property (IP) status of the SBIR-funded technology and of the business operating the technology
  • The underlying strength of this technology, as indicated by expressed interest by end-users and partners
  • Understanding of revenue prospects, funding channels and potential partnerships
  • Expression of realistic potential for the business itself
  • Identification and understanding of the obstacles, gaps and deficiencies of the technology and the business and timeframe to resolve them
  • Available resources (current) and anticipated (future) to fill gaps and accomplish goals

The most successful applicants will be those committed to the commercialization of the technology, and to the realistic expression and development of the current business model (whether or not it is built around a single technology). Applicants should also be clear in their expression of commercialization goals, the identification of gaps and deficiencies and the understanding of the resources that may be needed in commercializing a product or service.

NIH Offers Commercialization Assistance Program to Phase II SBIR and STTR Awardees

Notice Number: NOT-OD-14-110

Key Dates - Release Date: August 1, 2014

Related Announcements: None

Issued by National Institutes of Health (NIH)

Purpose

The purpose of this Notice is to announce the availability of a Commercialization Assistance Program (CAP) for NIH SBIR and STTR Phase II awardees. Now in its tenth year, this program is designed to help NIH SBIR-STTR Phase II awardees transition their SBIR-STTR-developed products into the marketplace. Through a contract with Larta Inc. of Los Angeles, California, the CAP will provide early stage companies with individualized assistance toward accomplishing their commercialization goals.

The 2014 CAP will begin in September 2014 and will conclude at the end of June 2015. The Commercialization Assistance Program is appropriate for the majority of NIH SBIR and STTR Phase II companies. Specifically, eligible companies include those with an NIH SBIR-STTR Phase II project (grant, contract, or cooperative agreement) that is or was active in the past five years, including Phase IIB competing renewal awards and those in the second phase of the Fast-Track program. Awardees from the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) can also apply. Participants must, however, meet the SBIR-STTR small business eligibility criteria as described in the current SBIR and STTR Parent Funding Opportunity Announcement available from the NIH Small Business Funding Opportunities website http://sbir.nih.gov. Those who may have previously participated in the program no more than two (2) times may participate again providing they have a different qualifying Phase II award. However, companies that are first time applicants to the CAP will be given priority.

The CAP is a 9-month long mentoring and training program. It is not a curriculum-based approach and should not be perceived as continuous 9 months of engagement. Instead, each participant works individually at their pace with assigned industry expert called the Principal Adviser (PA) and other current industry experts in business areas relevant to the participating company's technology space and commercialization needs to achieve program goals. The program is aimed at assisting participants with evaluating their commercialization options based on their specific technologies (including the need and prospect for investment, strategic partnerships or licensing) and to develop a solid market-entry plan covering an 18-month period. The assistance rendered under CAP is practical and actionable, oriented to addressing gaps that exist in your current commercialization status, and will allow a company to fully articulate a compelling case for market channels relevant to your business and to develop a clear understanding of potential customers, partners, investors and competitors. These goals are achieved from contact with experienced advisors and live feedback from current industry executives and others. Company CEO participation is highly encouraged and expected in this program.

The NIH CAP offers opportunities to both “emerging companies” i.e. new to, or with limited experience in the commercial marketplace and “seasoned companies” with more established commercialization experience who are facing more complex business strategic challenges. The program is customized to meet the needs of emerging and seasoned companies in three distinct tracks, each different in its objectives and outcomes: The Commercialization Training Track (CTT) for emerging companies, the Accelerated Commercialization Track (ACT), and the Regulatory Training Track (RTT). The CAP’s eighty (80) available slots will be distributed between the three tracks:

Commercialization Training Track (CTT) - This track will apply to the majority of NIH SBIR/STTR Phase II companies. It is aimed at assisting participants with evaluating their commercialization options based on their specific technologies (including the need and prospect for investment, strategic partnerships or licensing) and to develop a solid market-entry plan (“Commercialization Roadmap”) covering an 18-month period. It also assists participants in the development of market-appropriate tools to accomplish these objectives, and provides opportunities for direct industry feedback in live session. Participants work one-on-one with a principal advisor and industry experts as needed.

Accelerated Commercialization Track (ACT) - This track will apply to a selected group of NIH-funded companies who have successfully commercialized products and/or services, generated revenue, established partnerships and/or otherwise achieved a level of market development that is sustainable over a definitive period. However, they may need to address a specific applicable issue (such as a license-focused IP strategy or a term sheet for investors) whose resolution is key to their continued growth. This track specifically deploys domain experts to help participants achieve these outcomes.

Regulatory Training Track (RTT) – This track will apply to a selected group of NIH-funded companies whose technologies require regulation by the Food and Drug Administration (FDA). These companies are either preparing for initial engagement with and submission to the FDA or have already done so but may need to address specific applicable issues related to their application, developing a solid regulatory plan or addressing feedback from the FDA in order to move their technology development along toward achieving regulatory milestones and approval. This track specifically deploys regulatory business experts to help participants achieve these outcomes.

CAP participation is free of charge for the selected companies; however, participants are responsible for travel and lodging expenses associated with attending two mandatory workshops, one being a kick off event at the beginning of the program launch in Los Angeles, CA and another mid-way through the CAP called Feedback Sessions that are individual closed business strategy and partnering sessions with industry experts. The Feedback Sessions will be held in Washington, D.C. and Los Angeles, CA. NOTE: NIH will not provide additional funding for this purpose; however, participants with a currently active Phase II SBIR-STTR award may re-budget funds within the total costs awarded to cover allowable travel expenses for CAP events without NIH prior approval unless the re-budgeting action constitutes a change in scope or if the terms of award prohibit the use of funds for this purpose.

Detailed program information and application instructions are available on the CAP webpage. The deadline for submitting an application is September 2, 2014. Eighty (80) companies will be selected to participate in this year’s NIH CAP by the end of September 2014.

Inquiries

Please direct all program inquiries to:

Lenka Fedorkova, Ph.D.
CAP Program Manager,
Assistant Manager
SBIR/STTR Programs Office of the Director
National Institutes of Health
6705 Rockledge Drive, Suite 350 Bethesda, MD 20892
Telephone: (301) 435-0921 FAX: (301) 480-0146
Email: sbir@od.nih.gov

Please direct inquiries related to submission of the web application to:

Judy Hsieh
Programs Manager
Larta Institute
606 Olive Street, Suite 650 Los Angeles, California 90014
Telephone: 213-538-1444
E-mail: jhsieh@larta.org

CAP Data

Following the completion of the program, SBIR/STTR CAP participants are tracked for an 18-month period in two 9-month intervals. Commercialization data from a baseline period which spans the duration of the program is also collected. These reports provide progress tracking results for each year’s participants and are only summaries of the data. Quantifiable data such as number of deals and partnerships, revenue, and growth in equity funding are included as well as data indicating the participants' perceived impact the program had on their commercialization progress.

To view some of this data and other highlights from the CAP program, please view the NIH CAP Progress Reports:

 

2007-2008

Adobe Acrobat iconbaseline
(186 KB)

2006-2007

Adobe Acrobat iconbaseline
(187 KB)

Adobe Acrobat icon1st tracking interval
(198 KB)

Adobe Acrobat icon2nd tracking interval
(254 KB)

2005-2006

Adobe Acrobat iconbaseline
(193 KB)

Microsoft Word icon1st tracking interval
(170 KB)

Microsoft Word icon2nd tracking interval
(175 KB)

2004-2005

Adobe Acrobat iconbaseline (349 KB)

Adobe Acrobat icon1st tracking interval
(179 KB)

Adobe Acrobat icon2nd tracking interval
(166 KB)

 

NIH CAP: Breeding success, one company at a time 2004-2013

See information about the commercialization progress previous CAP participants made between 2004 and 2013. This data was collected at the conclusion of each year's program and again at two nine-month intervals.

NIH CAP Virtual Showcase

The technologies showcased are those which have been developed through the NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program. Each company listed has participated in the NIH SBIR Commercialization Assistance Program (CAP). Potential strategic partners and investors are encouraged to peruse the business opportunities offered here and contact the companies directly for those of interest.

Disclaimer Note: Information contained on this site neither constitutes nor should be inferred to be an endorsement or recommendation by NIH. 

Participants:

CAP in Detail

What is CAP?

The NIH Commercialization Assistance Program (CAP), offered annually since 2004, is designed to help some of the agency's most promising small life science and healthcare Phase II grantees develop their commercial businesses and transition their SBIR/STTR-funded technologies into the marketplace. Applicants are selected via a competitive process for a limited number of slots in the program.

Funded by NIH and managed through a contracting vendor, the CAP provides selected participants with individualized assistance toward accomplishing their commercialization goals. This is achieved through individual mentoring and consulting sessions, training workshops, access to domain experts and focus on outcomes that will enhance the commercialization profile and readiness of participating grantees.

The application period for NIH SBIR/STTR Phase II awardees is currently closed and expected to open sometime in 2014. All applications will be competitively reviewed, and participants will be notified if they’ve been accepted. This year we expect to accept 75 companies into the program. The assistance through CAP spans nine (9) months.

Who is Eligible to Participate?
  • Companies whose NIH SBIR and STTR Phase II award is or was active in the past 5 years, including Phase IIB competing renewals (grant, contract, or cooperative agreement) and those in the Fast-Track program. Projects that ended before August 2007 are not eligible.
  • Companies that meet the current SBIR/STTR small business eligibility criteria as described in the NIH SBIR/STTR Omnibus solicitation. (The solicitation and its parent funding opportunity announcements are available from the NIH Small Business Funding Opportunities website)
  • Previous NIH CAP participants with a different Phase II award. Please note that first time applicants to the CAP will be given priority due to the limited number of slots.
Is CAP Right for You?

The NIH CAP offers opportunities to both “emerging companies” new to the commercial marketplace and “seasoned companies” with more established commercialization experience and are facing more complex business strategic challenges. The program is customized to meet the needs of emerging and seasoned companies in two distinct tracks, each different in its objectives and outcomes: The Commercialization Training Track (CTT) for emerging companies, and the Accelerated Commercialization Track (ACT). The CAP's seventy five (75) available slots will be distributed between the two tracks as follows:

  • Commercialization Training Track (CTT) - With sixty (60) slots available, this track will apply to the majority of NIH SBIR/STTR Phase II companies. It is aimed at assisting participants with evaluating their commercialization options based on their specific technologies (including the need and prospect for investment, strategic partnerships or licensing) and to develop a solid market-entry plan (“Commercialization Roadmap”) covering an 18-month period. It also assists participants in the development of market-appropriate tools to accomplish these objectives. Participants work one-on-one with a principal advisor and industry experts as needed.
  • Accelerated Commercialization Track (ACT) - With fifteen (15) slots, this track will apply to a select group of NIH-funded companies who have successfully commercialized products and/or services, generated revenue, established partnerships and/or otherwise achieved a level of market development that is sustainable over a definitive period. However, they may need to address a specific applicable issue (such as a solid regulatory plan, a license-focused IP strategy or a term sheet for investors) whose resolution is key to their continued growth. This track specifically deploys industry experts to help participants achieve these outcomes.

The commitment of time and resources with management support is vital.Company CEO participation is highly encouraged and expected in this program. Past experience indicates that the best results are achieved when the CEO serves as the company's CAP Leader and is actively involved. Hence, successful applicants will be those where top management - founder, CEO, or other key team member leading the commercialization efforts - are directly involved in the Program.

CAP participation is free of charge for selected participating companies; however, participants in both, the ACT and CTT tracks, are responsible for travel and lodging expenses associated with attending the mandatory Commercialization Training Workshop (CTW) and, in the case of CTT track participants, for one Industry Feedback Session.

NOTE: NIH will not provide additional funding covering your participation in CAP; however, participants with a current active Phase II SBIR or STTR award may rebudget funds within the total costs awarded, to cover allowable travel expenses for CAP events without NIH prior approval unless the rebudgeting action constitutes a change in scope or if the terms of award prohibit the use of funds for this purpose. Selected companies are encouraged to contact their funding NIH institute program officer for inquires in this regard.

1. Commercialization Training Track (CTT)

The Commercialization Training Track (CTT) applies to the majority of NIH SBIR Phase II companies. Sixty (60) slots are available. CTT is aimed at assisting participants with evaluating their commercialization options based on their specific technologies (including the need and prospect for investment, strategic partnerships or licensing) and to develop a solid market-entry Commercialization Roadmap (a strategic action plan) covering an 18-month period. It also assists participants in the development of market-appropriate tools to accomplish these objectives.

Over a 9-month period, each CTT participant will:

  • Participate in an Orientation Webinar
  • Be Assigned a Dedicated Principal Advisor and Develop a Work Plan
  • Participate in a Commercialization Training Workshop
  • Perform Business and Strategic Planning and develop a Management Toolkit
  • Develop a Quad Chart and Keywords
  • Participate in a mid-point Feedback Session
  • Provide Program Feedback and Tracking

CAP Timeline CTT Companies

CAP Timeline CTT Companies

By the completion of the program, each participant should have a solid understanding of the commercial value of their technology, and also how it is positioned in the current market landscape, what the true competitive posture of the company is, and what gaps remain to be addressed. Each participant will have developed their own Management Toolkit which includes an 18-month Commercialization Roadmap (strategic action plan) that addresses their next steps.

CTT Orientation Webinar

All participants are expected to participate in the Orientation Webinar, which will cover the following topics:

  • An introduction to the program and to some of the key people associated with the program.
  • Guide to the program timelines, specific guidelines on your Road Show Presentation and 18-Month Commercialization Roadmap (strategic action plan)
  • Sample documents and resources available via the program
  • Introduction and Orientation to the NIH CAP portal
  • Discussion concerning program expectations

Principal Advisor Assignments and Work Plan Development

Upon selection as a CTT participant, a Principal Advisor (PA) is assigned to work closely with each participant and is matched with the company based on the advisor's experience and expertise and the company's needs. Your PA operates as a facilitator and counselor, helping you to prepare materials as needed, and serving as a sounding board throughout the program as you develop an 18-month Commercialization Roadmap (your Strategic Action Plan). Participants work one-on-one with their PA on a regular monthly basis, and other investment and/or industry advisors/experts will be consulted when warranted. The PAs are experienced consultants and business executives with recorded success in guiding innovative enterprises. Advisors will not do the work for you, but will mentor, guide, and assist. All participants will be coached and mentored via face-to-face meetings and/or via remote communication tools, e.g., phone, email, Internet.

Your first communications with your PA will focus on your commercialization needs and developing a program work plan that identifies obstacles and hurdles you face (or are likely to face) and broad outlines of solutions available to you. This plan is referred to as the CAP Planning/Assessment Template ("Template") and will be completed at the onset of the program to guide your work through the program. The Template will help identify gaps in operations, systems, technology product development, etc. and will be useful in defining the optimal path to market and commercialization. It is also used to align with the steps participants need to take to resolve the gaps, and thus to develop an 18-month Commercialization Roadmap (strategic action plan).

During this phase of the CAP, you and your PA will also prepare for your face-to-face meeting at the program's Commercialization Training Workshop, to take place in January, 2012.

Commercialization Training Workshop

(The CEO or other top management team member(s) with oversight and authority over commercialization issues is strongly encouraged to attend.)

All participants (ACT & CCT) are required to attend the Commercialization Training Workshop (CTW). All participants are responsible for travel and lodging expenses associated with attending this mandatory event. This workshop offers in-depth interactive seminars led by advisors and experts from the legal, investment, and industry communities. A key feature is a face-to-face meeting with your Principal Advisor (PA). The CTW also provides excellent opportunities to network with fellow CAP participants, other key people associated with the program, industry experts in attendance and NIH staff. Interactive seminars

Agenda topics may include but are not restricted to:

  • Financing and Funding Issues for Life Science Companies
  • Partnering/investment Planning
  • Intellectual Property Management
  • Early Stage Branding and Marketing issues and concerns (including social media)
  • Healthcare IT Commercialization Issues (for those companies in the Healthcare/IT field)
  • Regulatory and Reimbursement Issues

Face-to-Face Meeting with your Principal Advisor

A 1-hour face-to-face meeting with your PA will be scheduled the day after the workshop. It will be a continuation of your earlier discussions with your PA and will include an in-depth discussion of the company's status, commercialization needs, and the work plan (Planning/Assessment Template). Participants will also discuss various elements of the program including program timeline and the program's management toolkit. At the end of this meeting, there should be a clear understanding of all program details, a customized commercialization approach, and a firm commitment from the participant to invest the required time and effort to the CAP.

Business and Strategic Planning and Development of Management Toolkit –

After the CTW, companies and PAs start working on the work plan agreed upon and the development of the Management Toolkit, which will include materials useful for implementing their commercialization plan both during and after the program ends. While the Toolkit will be customized for each participant's needs, it will include information relevant to the following components:

18-Month Commercialization Roadmap (also referred to as the Roadmap or strategic action plan). At the end of the program, each company will have a list of strategies, tasks and milestones with a timeline looking forward over the next 18 months. Ideally, this would include budgets necessary to accomplish the necessary tasks, and may be broken down by specific periods over the course of the 18 months covered by the Roadmap. This tool will be useful in managing and tracking your commercialization progress and outcomes after the CAP.

Road Show Presentation: This is a short PowerPoint presentation to "pitch" the company to potential investors, strategic partners, licensees or customers. It will provide a brief, informative and compelling glimpse of the company, to attract the interest of a targeted audience at private meetings or at pitch events such as investment forums, conferences, or trade shows. (Note: This is not intended to serve as preparation for a specific event nominated by CTT participants, nor is there a commitment to performing this task for that purpose).

Quad Chart/Virtual Showcase and Keywords

Each company will develop a quad chart that can be used for showcasing and promoting the company's technology assets, including on NIH's Web site and portal. Each chart will include: (1) specific company information, (2) your management team, (3) an overview of your technology and its competitive advantage(s), and (4) your company's pipeline of products under development or a detailed description of the technology.

Feedback Sessions

Feedback Sessions are face-to-face working meetings for the participant to present its Commercialization Roadmap (18-month Strategic Action Plan) to a group of mentors and life science industry experts for critique and constructive feedback. Only CTT participants are expected to attend. (See previous note regarding travel costs.) These outside experts will provide objective and frank feedback on the company's commercialization opportunity and strategy (as presented) with fresh perspectives and, perhaps, suggestions and options other than those presented. You will have the opportunity to adjust and amend materials in your Management Toolkit based on the advice and recommendations provided. In addition, you will have the unparalleled opportunity to meet and network with industry experts, thus providing you contacts for future reference. Feedback Sessions are widely considered to be a major highlight and distinguishing feature of NIH's CAP.

Feedback Sessions are designed to be as convenient as possible for participating companies, and also to cultivate networking. Following the Feedback Sessions, participants will continue to work with their PAs on refining their strategies, action plans, presentations, and other Management Toolkit documents. If there is a need for other advisors from a particular specialty area, e.g. legal, regulatory, etc., such expertise may be brought in during this period as well.

Close-out Web Meetings

A Close-out Web Meeting is the final CAP event. This is an opportunity for the participant to provide NIH program managers, your Principal Advisor and key program staff a "live" look at the company's progress at the end of the program. The primary focus of this event is for you to present to NIH SBIR/STTR program managers the feedback received from the Feedback Sessions, what you and your company has accomplished since the Feedback Sessions, your 18-month Action Plan (next steps/goals), and your plan to achieve the milestones set out in the Plan. The meeting is informal, similar to the monthly teleconferences with the Principal Advisor, and will last approximately 30 minutes. A Web tool will be used to facilitate the sharing of the documents being discussed.

Program Feedback and Tracking - At completion of the program

All participants will be expected to provide feedback to NIH concerning their experiences with the program as well as commercialization tracking information for 18 months in three intervals: (1) Baseline: immediately upon completion of the program, (2) First Interval Tracking: nine months following completion, and (3) Second Interval Tracking: eighteen months following the program's completion.

The feedback will allow NIH to assess the program and its implementation, and the tracking will keep NIH informed of the progress your company has made with commercializing the NIH SBIR-developed product.

2. Accelerated Commercialization Track (ACT)

The Accelerated Commercialization Track (ACT) of the NIH-CAP applies to a select group of NIH-funded companies who have successfully commercialized products and/or services, generated revenue, established partnerships and/or otherwise achieved a level of market development that is sustainable over a definitive period. However, in this particular technology under which they have enrolled in CAP, they may be lacking with respect to (may need to address) a specific applicable issue (such as a solid regulatory plan, a license-focused IP strategy or a term sheet for investors), whose resolution is key to their continued growth. This track uses industry experts (called “expert resources”) to help participants achieve these outcomes. 15 slots are available for the Accelerated Commercialization Track.

During the program, each ACT participant will:

  • Participate in the ACT Orientation Webinar
  • Be Assigned a Dedicated the Principal Advisor and Develop an Outcome Proposal
  • Participate in a Commercialization Training Workshop
  • Develop a Transaction-Oriented Work Plan
  • Develop a Quad Chart and Keywords
  • Submit a Final Outcome Report
  • Provide Program Feedback and Tracking

CAP Timeline ACT Companies

CAP Timeline ACT Companies

The following are the key identifiable phases of the ACT track, in sequence.

ACT Orientation Webinar

All ACT participants are expected to participate in the ACT Orientation Webinar, which will feature the following topics:

  • Introduction to the program and to some of the key people associated with the program (including “expert resources” who may assist with the resolution of your outcome).
  • Orientation with program timeline, specific guidelines on your Outcome Proposal and Final Outcome Report
  • Sample documents and resources available via the program
  • Introduction and Orientation to the NIH-CAP Portal
  • Discussion concerning program expectations

Principal Advisor Assignments and Outcome Proposal Development –

Upon selection as an ACT participant, a Principal Advisor (PA) is assigned to work closely with each participant and is matched with the company based on the advisor's experience and expertise and the company's needs. Your PA operates as a facilitator and counselor, helping you to prepare materials as needed, and serving as a sounding board throughout the program as you develop, and work towards the achievement of, a Targeted Outcome for the CAP. Participants work one-on-one with their PA on a regular monthly basis. The PAs are experienced consultants and business executives with recorded success in guiding innovative enterprises. Advisors will not do the work for you, but will mentor, guide, assist and generate strategic connections for you. All participants will be coached and mentored via face-to-face meetings and/or via remote communication tools, e.g., phone, email, Internet.

Your first communications with your PA will focus on the development of an "Outcome Proposal." The parties will discuss the companies' most critical commercialization issues in order to focus on developing a “Targeted Outcome” to be accomplished during the program. Targeted outcomes may include, but are not limited to, addressing regulatory issues, legal and/or financial structuring/restructuring, management recruitment, term-sheet development, product or prototype design or other issues. Whether a specific outcome is appropriate for the company is determined in discussions between the PA and the Company. A single targeted outcome will become a part of an Outcome Proposal which will discuss the participant's proposed approach to achieve the targeted outcome. The Proposal will spell out clearly the most critical issues pertinent to creating a desired solid commercialization outcome, what the targeted outcome will be (e.g. a "regulatory guidance" document, a design, a recruit), the best path of resolution within a timeline consistent with the duration of the program, and any "expert resources" who may be needed to achieve the targeted outcome. NIH must approve this Outcome Proposal before moving forward in the program.

Commercialization Training Workshop

(The CEO or other top management team member(s) with oversight and authority over commercialization issues is strongly encouraged to attend.)

All participants (ACT & CCT) are expected to attend the Commercialization Training Workshop (CTW). All participants are responsible for travel and lodging expenses associated with attending this mandatory event. This workshop offers in-depth interactive seminars led by advisors and experts from the legal, investment, and industry communities. A key feature is a face-to-face meeting with your Principal Advisor (PA). The CTW also provides excellent opportunities to network with fellow CAP participants, other key people associated with the program, industry experts in attendance and NIH staff.

Interactive Seminars and Networking Workshops

Agenda topics may include but are not restricted to:

  • Financing and Funding Issues for Life Science Companies
  • Partnering/investment Planning
  • Intellectual Property Management
  • Early Stage Branding and Marketing issues and concerns (including social media)
  • Healthcare IT Commercialization Issues (for those companies in the Healthcare/IT field)
  • Regulatory and Reimbursement Issues

Face-to-Face Meeting with your Principal Advisor

A 1-hour face-to-face meeting with your PA will be scheduled the day after the workshop. It will be a continuation of your December discussions with your PA and will include an in-depth discussion of the company's status, commercialization needs, and your targeted Outcome, the Outcome Proposal. One of the items for discussion between the PA and the ACT company is the type of "expert resource" necessary to help accomplish the nominated Outcome. Participants will also discuss the program timeline and other program deliverables. At the end of this meeting, there should be a clear understanding of all program details and a firm commitment from the participant to invest the required time and effort to the CAP.

Transaction-Oriented Work Plan

Upon NIH approval of the Outcome Proposal, the participant will work with his/her PA to complete the transaction-oriented work plan. The work plan should clearly indicate a specific need and a clear path to accomplish a tangible outcome and will include a timeline with specific milestones, and an estimated date for completion. The plan should be capable of being accomplished within the duration of the program.

ACT companies are also provided with the assistance of Expert Resources (ER), who are professionals identified jointly by each ACT company and its PA as critical to the achievement of the targeted outcome. ERs are experts in critical aspects of commercialization, such as intellectual property, regulatory clearance, accounting, management recruiting, government procurement, etc. The assistance provided by the PAs and ERs during the course of the CAP is fully covered by the NIH; participants should use these resources only for the length and scope directed by the program. However, participants are free to negotiate contingency arrangements with a provider of services of their choice for work that may endure beyond the CAP, covered by their own financial resources.

* Disclaimer: NIH does not endorse the expert resources/advisors for the purpose of retaining them for any purpose following the conclusion of the Program. Any arrangement with such resources/advisors beyond the service rendered under the program is the responsibility of the CAP participating Company ONLY.

Quad Chart/Virtual Showcase and Keywords

Each company will develop a quad chart that can be used for showcasing and promoting the company's technology assets, including on NIH's Web site and portal. Each chart will include: (1) specific company information, (2) your management team, (3) an overview of your technology and its competitive advantage(s), and (4) your company's pipeline of products under development or a detailed description of the technology.

Final Outcome Report - Near completion of the program

Working with the company, the PA will prepare a Final Outcome Report that documents the participant's progress and end-results with meeting the company's desired outcome. It will address whether the timeline and work plan were adhered to throughout the program and if the desired outcome was accomplished. In cases where the desired outcome is not reached, the Final Outcome Report will specify the key issues that prevented the outcome from occurring and the company's next steps towards achieving the targeted outcome.

Close-out Web Meetings

A Close-out Web Meeting is the final CAP event. This is an opportunity for the participant to provide NIH program managers, your Principal Advisor and key program staff a "live" look at the company's progress at the end of the program. The primary focus of this event is for you to present to NIH SBIR/STTR program managers what your company has accomplished on the targeted outcome, your Transaction-Oriented Work Plan, and your strategy to achieve the milestones set out in the Work Plan. The meeting is informal, similar to the monthly teleconferences with the Principal Advisor, and will last approximately 30 minutes. A Web tool will be used to facilitate the sharing of the documents being discussed.

Program Feedback and Tracking - At completion of program

All participants will be expected to provide feedback concerning their experiences with the program as well as commercialization tracking information for 18 months in three intervals: (1) Baseline: immediately upon completion of the program, (2) 1st Interval Tracking: nine months following completion, and (3) 2nd Interval Tracking: eighteen months following the program's completion. The feedback will allow NIH to assess the program and its implementation, and the tracking will keep NIH informed of the progress your company has made with commercializing the NIH SBIR-developed product.

 

Contact

NIH
Lenka Fedorkova, Ph.D.
Assistant Program Manager
SBIR/STTR Program Office
Office of Extramural Programs
National Institutes of Health
Ph: (301) 435-0921
Email: sbir@od.nih.gov
http://sbir.nih.gov

Larta, Inc.
Judy Hsieh Senior
Program Manager
Larta, Inc.
Ph: (213) 538-1444
jhsieh@larta.org

Page Last Updated on October 15, 2014.
Search Options:
SBIR Virtual Showcase Results:
Company Name/Profile text Program
Year
File Size Grant/Contract
Support
Industry Sector Key Words

Abratech Corp.

 
 
 
 

2008-2009

PDF - 1055 KB

2R44NS041776-03

Medical Devices

QSD, Q-sequence deconvolution, A-waves, G-waves, evoked-responses

 

Acelot, Inc.

 
 
 
 

2009-2010

PDF - 52 KB

5R44MH086121-03

Drug discovery

Lead Identification, Lead Optimization, Graph-based modeling, Structure activity relationship, Topological search & mining

 

Acoustic MedSystems

 
 
 
 

2007-2008

PDF - 132 KB

2R44CA99374

Medical Devices

ultrasonic therapy

 

ADA Technologies, Inc.

 
 
 
 

2009-2010

PDF - 68 KB

2R44RR023763-02

Carbohydrate and Biology Research

Carbohydrates, Glycobiology research, Microarray slides, Medical research, Cancer detection

 

Adarza BioSystems Inc.

 
 
 
 

2009-2010

PDF - 52 KB

2R44ES016406-03

biosensor technology

Lab-on-a-chip, Diagnostics, Biosensor, Microarray, Label-free

 

Advanced Cell Diagnostics, Inc.

 
 
 
 

2008-2009

PDF - 150 KB

2R44CA122444-02A1

Biotech/Pharmaceutical

in-situ, RNA, detection, biomarker, validation

 

Advanced Circulatory Systems

 
 
 
 

2007-2008

PDF - 82 KB

5 R44 HL065851

Medical Devices

Resuscitation systems

 

Advanced Hearing Concepts

 
 
 
 

2009-2010

PDF - 74 KB

5R44DC006765-03

Hearing Rehabilitation

hearing, hearing rehabilitation, hearing impaired, hearing aid

 

Aerodyne Research, Inc.

 
 
 
 

2009-2010

PDF - 73 KB

5R44HL081951-03

Advanced scientific instrumentation; Medical devices

Breath analysis, disease biomarker, asthma, real-time monitor

 

Aerophase

 
 
 
 

2009-2010

PDF - 75 KB

5R44CA096409-03

Pharmaceuticals

lung, cancer, aerosol, paclitaxel, inhalation

 

AfaSci

 
 
 
 

2007-2008

PDF - 109 KB

5 R44RR017182-03

Instruments for Research and Drug discovery

drug discovery

 

AgentSheets,Inc.

 
 
 
 

2008-2009

PDF - 85 KB

5 R44 RR011008-03

Education

science education, physiology, interactive, collective simulation, STEM education

 

AJ Medical Devices

 
 
 
 

2007-2008

PDF - 121 KB

5R44HL069608

Medical Devices

cardiac arrest, monitor, implanted, wireless, EMS

 

Akaza Research

 
 
 
 

2007-2008

PDF - 158 KB

2R44RR19837-03A1

eClinical Solutions

eClinical, EDC, informatics, open source, software

 

Akina, Inc.

 
 
 
 

2009-2010

PDF - 130 KB

2R44RR024253-02A1

Drug Delivery/Medical Device/Research Products

Biodegradable polymer, fast-melting tablets, nanoparticles, drug delivery technologies, fluorescent probes

 

Aktiv-Dry LLC

 
 
 
 

2008-2009

PDF - 77 KB

4R44DA022096-02

Biotechnology specializing in inhalable powder formulation, manufacture, and delivery

Respiratory drug delivery,Nano- and micro-powder processing, Pulmonary delivery, Inhaled vaccines, PuffHaler® DPI

 

Alias-i

 
 
 
 

2008-2009

PDF - 113 KB

2R44RR020259

Bioinformatics

bioinformatics, data mining, lingpipe, genetics, search

 

Allied Innovative Systems

 
 
 
 

2007-2008

PDF - 138 KB

2R44 AI 055310

Medical Diagnostics

medical diagnostics, Hepatitis B, HIV, Prostate

 

Allvivo Vascular, Inc.

 
 
 
 

2008-2009

PDF - 273 KB

5R44DK072560-03

Medical Devices, Combination Products

Biomimetic, Surface coatings, Medical devices, Combination products, Biomaterials

 

AlphaMed Inc.

 
 
 
 

2008-2009

PDF - 41 KB

2R44CA114920-02A2

Targeted radiopharmaceuticals

melanoma, cancer, oncology, targeted therapy, partnering

 

AnthroTronix, Inc.

 
 
 
 

2008-2009

PDF - 75 KB

2R44HD042353-02A2

Computer Input Devices

human factors, medical rehabilitation, instrumentation

 

APC Biotechnology Services

 
 
 
 

2009-2010

PDF - 85 KB

2 R44 GM081945-02

Biotechnology

peptide, manufacture, scalable, economical, vaccine

 

ApoImmune, Inc.

 
 
 
 

2008-2009

PDF - 316 KB

2R44AI071618-02

Biotechnology, Novel Immunotherapies and Vaccines

Cancer Therapeutics, Infectious Disease Vaccines, Immunotherapy, Adjuvants, Cell Therapy

 

Applied Medical Visualizations

 
 
 
 

2008-2009

PDF - 992 KB

R44-HL079783-02

Medical Information Technology, Clinical Decision Support

AIM system, Patient information system, Anesthesia, Electronic Documentation, EMR

 

Applied Scientific Research

 
 
 
 

2007-2008

PDF - 120 KB

9R44RR024300-02A1

Software; Computer Aided Engineering (CAE)

Computer Aided Engineering (CAE), Biofluid FLow Simulation, Design Optimization, Cardiovascular/pulmonary Assist Devices, Drug Aerosol Flow

 

Archimage

 
 
 
 

2007-2008

PDF - 97 KB

4U44 DK66724

Healthcare media

videogames, video, games, health, play

 

Archivex

 
 
 
 

2011-2012

PDF - 54 KB

2R44GM077768-02

Products for Laboratory Research and Drug Discovery

Liquid Archiving, LSystem, Drug Discovery, LSafe Cartridge, reduce contamination risk

 

Aronora Biopharmaceuticals

 
 
 
 

2011-2012

PDF - 312 KB

R44HL095315

Biotech

Stroke, thrombosis, heart attack, bleeding, coagulation

 

Arrayomics

 
 
 
 

2011-2012

PDF - 81 KB

5R44AI077249-03

Biotechnology

high-plex protein microarray assay, Biotechnology, ArrayESP, microarray scanners, Diagnostic

 

Artann Laboratories, Inc.

 
 
 
 

2008-2009

PDF - 96 KB

2R44AG17400-03

Medical Devices

medical device, elasticity imaging, bone ultrasonometry, osteoporosis detection, diagnostic imaging

 

Atmospheric Glow

 
 
 
 

2007-2008

PDF - 193 KB

2R44 GM062678-02

Disinfection/Sterilization

atmospheric plasmasterilization, medical devices, disinfection, infection

 

Auritec Pharmaceuticals

 
 
 
 

2008-2009

PDF - 41 KB

2R44NS049918-02

Drug Delivery

drug delivery, injectable plattform, small molecules, schizophrenia, Parkinson's Disease

 

Auxagen

 
 
 
 

2011-2012

PDF - 107 KB

5R44AR052578-03

Pharmaceuticals

TGF-ß receptor antagonist, wound healing, reducing scarring, tissue fibrosis, lung fibrosis

 

Azevan Pharmaceuticals, Inc.

 
 
 
 

2008-2009

PDF - 140 KB

R44MH063663

Pharmaceuticals

drug delivery, injectable plattform, small molecules, HIV, Parkinson's Disease

 

Behavioral Assessment, Inc.

 
 
 
 

2008-2009

PDF - 82 KB

5R44MH073180-03

Professional Behavioral Health Assessment and Intervention Services

Children, Stress, Mental Health, Assessment, Hispanics

 

Behavioral Tech Research, Inc.

 
 
 
 

2011-2012

PDF - 108 KB

5R44MH081388-03

Psychotherapy training and implementation

Evidenced based therapy, Computer-assisted therapy, Therapy Outcomes Monitoring, Concurrent documentation, Dissemination

 

Berkeley Analytics, Inc (DBA NutritionQuest)

 
 
 
 

2009-2010

PDF - 44 KB

4R44AG032241-02

Wellness Intervention

Wellness coaching, nutrition, physical activity, evidence-based, research analysis

 

Bio-Quick Corporation

 
 
 
 

2009-2010

PDF - 58 KB

2R44CA115041-02

Medical Devices

tissue, biospecimen, histology, pathology, medical device, fast tissue preservation, tissue fixation and processing, ultrasound facilitated tissue preservation, Biospecimen standardization, Biomolecule integrity and recovery, Reducing surgical diagnosis turnaround time, Maximizing biomolecule integrity and recovery, Minimizing preanalytical variables

 

Bioanalytical Systems, Inc.

 
 
 
 

2008-2009

PDF - 316 KB

5R44RR022489-03

Life Science Instrumentation

pharmacokinetics, pharmacodynamics, automated, blood, sampling

 

BioFormatix

 
 
 
 

2007-2008

PDF - 142 KB

5 R44 EY014077-03

Biomedical software and devices

perimetry, glaucoma, diagnostic aid software, visual field

 

BioFormatix, Inc.

 
 
 
 

2009-2010

PDF - 58 KB

2R44EY015373-03A2

Biomedical software and devices

portable perimeter, visual field test, head mounted display, glaucoma screening, vision testing

 

BioHesion

 
 
 
 

2007-2008

PDF - 108 KB

5R44CA101579-03

Biotechnology / Research Services

BioSensor, BioMaterials, Gold, Peptide, Research Services

 

BioMedware, Inc.

 
 
 
 

2008-2009

PDF - 88 KB

5R44CA117171-03

Software

biostatistics, epidemiology, GIS, software, spatial statistics

 

BIOMENS, LLC

 
 
 
 

2008-2009

PDF - 327 KB

5R44EY014739-03

Medical Devices (Opthalmology)

IOP,GDD,Diabetics, EMR, RFID technology

 

Bioptigen

 
 
 
 

2007-2008

PDF - 164 KB

2R44EY015585-02A1

Medical Devices, Imaging

Optical imaging technology

 

Bonenta,Inc.

 
 
 
 

2008-2009

PDF - 237 KB

2R44DE016771-02

Musculoskeletal Devices; Biological drug-eluting synthetic bone grafts and implants

Bone regeneration; osteogenesis; osteoinduction; spine; orthopedics

 

Bright Outcome

 
 
 
 

2007-2008

PDF - 113 KB

N44-PC-65023

Healthcare

Home management, chronic diseases

 

Brighton Technologies Group, Inc.

 
 
 
 

2008-2009

PDF - 212 KB

R44 AI063919-03

Medical Devices Coatings

Antimicrobial, coating, nosocomial, infection, medical device

 

Brown & Hebranson

 
 
 
 

2007-2008

PDF - 101 KB

5 R44-DE015232-023

3-D Interactive Software, Healthcare Education

3-D, Software, Healthcare education

 

Brown and Herbranson Imaging, Inc.

 
 
 
 

2009-2010

PDF - 48 KB

R44EB003067

Medical and Dental Educational Software

Human Anatomy, Medical/Dental Educational Software, 3-D images, Interactive images, on-line curriculum

 

Bruce Technologies Inc.

 
 
 
 

2009-2010

PDF - 147 KB

5R44RR019174-03

Medical Devices

PET/CT, cyclotrons, targets, radionuclides, radiopharmaceuticals

 

Caldera Pharmaceuticals

 
 
 
 

2011-2012

PDF - 199 KB

2R44AI79935-03

Biotechnology Instruments and Pharmaceuticals

XRpro®, drug-protein interactions, Biotechnology Instruments, x-ray fluorescence, proteomics

 

Caring Technologies

 
 
 
 

2007-2008

PDF - 118 KB

2R44HD052340

Health Care Information Technology

autism, health care information technology (HCIT), telehealth, rural medicine, behavioral disorders

 

CellASIC

 
 
 
 

2007-2008

PDF - 138 KB

2R44CA117178-02

Life Science Instrumentation

microfluidics, cell-based screening, hepatocyte, invitro toxicology, primary cell screening

 

Centice Corporation

 
 
 
 

2011-2012

PDF - 242 KB

5R44GM075441

Biosensors

Biosensors, Coded Aperture Raman Spectroscopy, POC, high resolution multiple biomarker, mobile

 

CFD Research

 
 
 
 

2007-2008

PDF - 139 KB

2 R44 HL076034-02

Pharma/Biotech (Instrumentation/Tools)

microfluidics, cell, nanoparticle, delivery, adhesion

 

Ciencia, Inc.

 
 
 
 

2008-2009

PDF - 54 KB

2R44GM075407-02

Instrumentation for biomedical research and environmental monitoring

Surface Plasmon Resonance (SPR), Fluorescence, Research Instrumentation, Protein Microarray, Selective Cell Capture

 

Cognosci

 
 
 
 

2008-2009

PDF - 167 KB

2R44AG020473-05

Pharmaceuticals

Alzheimer's, pharmaceuticals, neurorestorative, anti-inflammatory, re-myelinating

 

Combinix, Inc.

 
 
 
 

2008-2009

PDF - 103 KB

2R44CA093099-02A2

Life Science and pharmaceutical research products

reagent fluorescence pharmaceutical calcium bioanalysis

 

Convergent Engineering

 
 
 
 

2011-2012

PDF - 111 KB

2R44HD056606-02

Medical Devices

eToco, fetal heart rate, electrodes, maternal uterine EMG, non-invasive fetal monitoring system

 

Creatv Microtech

 
 
 
 

2007-2008

PDF - 91 KB

2R44 CA094430

Diagnostics

in vitro diagnostics

 

Culmini Inc.

 
 
 
 

2009-2010

PDF - 53 KB

2R44DK074209-02

Healthcare IT

patient guide treatment success outcomes

 

customKYnetics, Inc.

 
 
 
 

2008-2009

PDF - 95 KB

4R44HD055019-02

Medical Devices

sports medicine, rehabilitation, ACL, TKA, electrical stimulation

 

Cyto Pulse Sciences, Inc.

 
 
 
 

2008-2009

PDF - 312 KB

5R44AI055212

Medical Devices and Instruments

DNA Vaccine delivery, Electroporation, Electrofusion, Prostate cancer, Hybridoma production

 

Danya

 
 
 
 

2007-2008

PDF - 143 KB

HHSN271200555274C

Healthcare Services

public health training

 

DEKK-TEC

 
 
 
 

2007-2008

PDF - 2 MB

5R44CA094566

Pharmaceuticals

pharmaceuticals, anti cancer, brain tumors, DM-CHOC-PEN

 

Dimera Incorporated

 
 
 
 

2007-2008

PDF - 103 KB

2R44HL074699

Cardiovascular research and development with an emphasis on women’s cardiovascular health

cardiovascular research, women's health

 

DVX, llc

 
 
 
 

2011-2012

PDF - 71 KB

HL095195

Medical Devices

Interventional cardiology, FAME and FFR, Coronary artery disease and stenosis, Peripheral artery disease, Ultrasound blood flow measurement

 

Dynaflow, Inc.

 
 
 
 

2009-2010

PDF - 58 KB

2R44EB005139-02A1

Research Tools

contrast agents, microbubbles, CFD,  target drug delivery, cavitation

 

Dynamic Clinical Systems

 
 
 
 

2011-2012

PDF - 77 KB

HHSN261201000086C

Healthcare Information Technology

oncology and spine care, PRO, real-time clinically meaningful reporting, Web-based and HIPAA-compliant, Healthcare Information Technology

 

ECI Biotech

 
 
 
 

2008-2009

PDF - 100 KB

2R44GM079834 - 02

Biotechnology

Diagnostics, Inexpensive, Rapid, Launch 2011, Innovation

 

EduMedia, Inc.

 
 
 
 

2007-2008

PDF - 140 KB

3R44CA063898-03

Healthcare Media

health media, wellness, aging, e-Health, disease prevention

 

Energetiq

 
 
 
 

2007-2008

PDF - 235 KB

2R44RR022488-02

Biological Imaging and Analysis

x-ray, microscope, ultraviolet, circular, dichroism

 

Engineering and Scientific Research

 
 
 
 

2007-2008

PDF - 95 KB

2R44HL078055-02A1

Medical Devices

respiratory disorders, respiratory diagnostic device

 

Eutropics Pharmaceuticals

 
 
 
 

2011-2012

PDF - 209 KB

5R44CA135915-03

Oncology Companion Diagnostics / Therapeutic

Myeloma, Targeted-therapeutic, Companion-diagnostic, Mcl-1, Mitochondria

 

Exemplar Genetics

 
 
 
 

2011-2012

PDF - 74 KB

2R44HL102950-02

BioMedical Research

BioMedical Research, Cystic Fibrosis, Liver Disease, Heart Disease, Cardiac Arrhythmia

 

Fairway Medical Technologies, Inc.

 
 
 
 

2008-2009

PDF - 151 KB

3R44CA128196

Medical Devices

image coregistration, noninvasive diagnostics of cancer, optoacoustic/photoacoustic, functional and anatomical imaging, blood oxymetry with spatial resolution

 

FFA Sciences LLC

 
 
 
 

2009-2010

PDF - 56 KB

DK073535-02

In Vitro Diagnostics (Blood Tests)

Diagnostics, fatty liver disease, jaundice, bilirubin, ischemia

 

First Light (Rapid Micro)

 
 
 
 

2007-2008

PDF - 135 KB

5R44AI055195-04

In vitro diagnostics

government contract, biodefense, invitro diagnostics, halthcare, ultra sensitive immunoassay

 

Fluential

 
 
 
 

2008-2009

PDF - 50 KB

4R44NR10072-02

Health Information Technology

patient safety, nurse patient communication, language interpretation, limited English proficient patients

 

FocalCool LLC

 
 
 
 

2009-2010

PDF - 79 KB

2R44HL088789-02A1

Medical Devices

Hypothermia, Guide catheter, Local cooling, Heart attack, Myocardial infarction

 

GeneCopoeia, Inc.

 
 
 
 

2009-2010

PDF - 61 KB

2R44CA124001-03

Biotechnology

Cancer therapeutics, p53 therapy, Protein replacement, therapy, p53-fusion protein, Protein drug development

 

GeneGo

 
 
 
 

2007-2008

PDF - 99 KB

2R44CA112828-02

Biomarkers

biomarkers, breast cancer

 

GENOFi LLC

 
 
 
 

2009-2010

PDF - 90 KB

5R44HG003658-03

Life Sciences

cDNA, RNA, isoform, drug, discovery

 

Genopsys, Inc.

 
 
 
 

2007-2008

PDF - 76K KB

5R44GM061445-04

Genetic Engineering, Proteinomics

Biopharmaceuticals, Biofuels, Agriculture

 

Glycobia

 
 
 
 

2011-2012

PDF - 107 KB

2R44GM088905-02

Biotechnology, Pharmaceuticals

Glycoproteins, Therapeutics, Glycosylation, Biotechnology, Bacteria

 

Goalistics

 
 
 
 

2011-2012

PDF - 116 KB

R44NS048743-04

Electronic Behavioral and Mental Health Applications

Online chronic pain management, Complementary chronic pain management, Internet pain management program, Behavioral health, Pain Self-Management

 

Healthcare Interactive

 
 
 
 

2007-2008

PDF - 126 KB

2R44 AG023451

Educational Software and Videos

internet based video training

 

HepatoSys, Inc.

 
 
 
 

2011-2012

PDF - 71 KB

2R44DK076350-02

Medical Devices and Research Products

therapeutic transplantation, provision of viable human cells, Restore organs for transplant, Isolation of human hepatocytes, research and toxicity testing

 

I.D.E.A.S., Inc.

 
 
 
 

2009-2010

PDF - 73 KB

2R44AG26170

Long-term Care

long-term care, elders, caregivers, assisted living, retirement communities

 

ID Fish Technology Inc.

 
 
 
 

2008-2009

PDF - 65 KB

2R44AI056785-02

Medical Devices

malaria, Tb., mycobacterium, RNA test, insitu hybridization

 

IDEA International, Inc.

 
 
 
 

2011-2012

PDF - 933 KB

2R44DE018062-02

Dental Education and Social Networking

Dental Education, inexpensive, portable, haptic technology device, social networking

 

IGAN Biosciences, Inc.

 
 
 
 

2011-2012

PDF - 97 KB

1R44DK083147-01A1

Pharmaceuticals

IgA protease, microbial proteolytic enzyme, kidney damage, biological therapeutic, drug development

 

ImmPORT Therapeutics Inc.

 
 
 
 

2008-2009

PDF - 150 KB

2R44AI058365-03

Biotech/Pharmaceutical

Protein microarrays, biomarkers, serodiagnostics, vaccines, antigen discovery

 

Infinite Biomedical Technologies

 
 
 
 

2007-2008

PDF - 169 KB

2R44HD042872

Medical Devices

neonatal monitoring, eeg, diagnostic, NICU, Neurology

 

InFlame Therapeutics

 
 
 
 

2009-2010

PDF - 112 KB

R44 NS052068

Development of Brain Neuroprotective Drugs, Diagnostic Biomarkers for Brain Inflammation

biomarker, brain, inflammation, Alzheimer, HIV, dementia, drug

 

Infoscitex

 
 
 
 

2007-2008

PDF - 128 KB

2 R44 HD047128-02

Medical Devices

Infoscitex, Active Bottle, Preterm Infant, Computer Controlled, Feeding Device

 

INFOTECH Soft, Inc.

 
 
 
 

2008-2009

PDF - 370 KB

2R44RR018667-03A1

Software Development

Software, biomedical research, information integration, Semantic Web, health information technology

 

INFOTECHSoft

 
 
 
 

2007-2008

PDF - 335 KB

HHSN261200622010C

Software development

software, healthcare, life sciences

 

Innovative Biologics

 
 
 
 

2007-2008

PDF - 134 KB

2R44AI052894-02

Medical Devices

MRSA, staph infection

 

Integral Molecular

 
 
 
 

2008-2009

PDF - 88 KB

5R44GM076779-03

Biotechnology Reagent / Platform Company

Structure Activity Relationship (SAR), Epitope Mapping, Membrane Proteins, High throughput mapping, Functional Regions

 

Intelligent Optical Systems

 
 
 
 

2008-2009

PDF - 525 KB

2R44CA108017-02A1

Optical sensing devices, software and instrumentation

Point of care assay, cancer screening, infectious disease diagnostic

 

InterScience, Inc.

 
 
 
 

2009-2010

PDF - 74 KB

5R44DK080566-03

Medical Devices

Endoscopy, Minimally invasive surgery, Omnidirectional imaging, Optical, Medical technology

 

Intrinsic BioProbes

 
 
 
 

2007-2008

PDF - 110 KB

5R44HL072671-03

Biotechnology

Biotech, Biotechnology, Proteomics, Biomarker, Protein

 

Investigen

 
 
 
 

2007-2008

PDF - 141 KB

2R44AI069574-02

Molecular Diagnostics

Rapid diagnostic, Nucleic Acid, Isothermal, Colorimetric, Tuberculosis

 

InvoTek

 
 
 
 

2007-2008

PDF - 236 KB

4R44HD053176

Assistive devices for persons with disabilities

computers, eye movement, speech

 

inXsol, LLC

 
 
 
 

2009-2010

PDF - 86 KB

2 R44 ES015697-02

Software (eLearning, Custom Software Design, Web-based applications)

Computer simulation, incident command, emergency incidents, web-based, software

 

ioGenetics LLC

 
 
 
 

2008-2009

PDF - 144 KB

5R44AI056944-05

Drug Discovery, Infectious Disease Therapeutics

drug discovery, infectious disease therapuetics,cryptosporidiosis, anti-infectives, antimicrobials

 

ISCHEM Corporation

 
 
 
 

2009-2010

PDF - 77 KB

2R44HL071470

Medical Diagnostics

plaque, vulnerable, cardiovascular, heart, stroke

 

ISOGENIS, Inc.

 
 
 
 

2008-2009

PDF - 288 KB

R44-DK69618

Biopharmaceutical

Gene Therapy, Regenerative Medicine, Tissue Engineering, Kidney Transplantation, Adenoviral Vector or Adenovirus,Organ and Cell Transplantation, Stem Cell Therapy

 

ISW Group

 
 
 
 

2007-2008

PDF - 108 KB

2R44AR05259202

Pharmaceuticals

pharmaceutical, dermatology

 

iVisit LLC

 
 
 
 

2008-2009

PDF - 46 KB

9 R44 AG033521-02

Software

Mobile health, disease management, object recognition, remote patient care, diabetes

 

Jambeyang

 
 
 
 

2007-2008

PDF - 157 KB

HHSN261200644000C

Medical Information Systems

electronic medical record, mammography, breast imaging, data collection, report generation

 

KeraMed Inc.

 
 
 
 

2009-2010

PDF - 78 KB

2R44EY016617-02A1

Medical Devices, Ophthalmology

ophthalmology, eye, medical device, implants, corena

 

Koning Corporation

 
 
 
 

2008-2009

PDF - 134 KB

1R44CA103236

Medical Devices

Breast, Cancer,Cone, Beam, CT

 

LasMed LLC

 
 
 
 

2011-2012

PDF - 68 KB

2R44DA016840

Biological Research Tools and Medical Devices

diode laser-based stimulators, Adelta/C, TRPV, Biological Research Tool, small nerve fiber neuropathies

 

Leap of Faith Technologies, Inc.

 
 
 
 

2008-2009

PDF - 88 KB

2R44AG022271-02A1

Telehealth, Telemonitoring, Telemedicine

Telemonitoring, telehealth, medication adherence, e-health

 

Lexitek, Inc.

 
 
 
 

2008-2009

PDF - 272 KB

2R44CA103610-02A2

Medical Devices, Optical Instrumentation

Radiotherapy, detector, proton beam, quality assurance, dosimetry

 

LifeSensors Inc.

 
 
 
 

2008-2009

PDF - 157 KB

2R 44 GM 068404-02

Biotechnology

SUMO, Ubiquitin, protein expression, microarrays, custom protein production, isopeptidase assays, SUMOstar, ubiquitome

 

LightSpin

 
 
 
 

2007-2008

PDF - 120 KB

2R44EB000929-02

Photodetector Component for Medical Imaging (PET)

Photodetector, Single-photon, SSMCP, PET, PET detector

 

LKC Technologies

 
 
 
 

2011-2012

PDF - 249 KB

5 R44 EY021121-03

Medical Devices

electrophysiology testing, Diabetic Retinopathy, ischemia, fast & accurate, screen diabetics

 

Looking Glass Analytics

 
 
 
 

2009-2010

PDF - 83 KB

5R44AA015650-03

Healthcare IT – Data Visualization and Analysis

Software, Analysis, Internet, Alcohol, GIS

 

Lucigen

 
 
 
 

2011-2012

PDF - 53 KB

5R44MH081380-02

Biotechnology: Life science research tools and advanced genomic and proteomic custom services

Lucigen GPCR Platform, GPCR, Molecular Structure, Functional Membrane Proteins, Drug Targets

 

Lucigen

 
 
 
 

2009-2010

PDF - 94 KB

2 R44 HG004095-02

Life Science research tools and services for cloning, amplification and NextGen DNA sequencing

Genomics, DNA sequencing, DNA polymerase, PCR, Cloning

 

Lynntech, Inc.

 
 
 
 

2008-2009

PDF - 83 KB

2 R44 HL081994-02

Diagnostics

on-site molecular analyzer, molecular diagnostics, pathogen detection, real-time PCR

 

Lynx Design

 
 
 
 

2011-2012

PDF - 107 KB

2R44NS070438-02

Over-the-counter health aides

Parkinson, QUIESSE, non-implanted device , Tremor, cost effective

 

mBio Diagnostics

 
 
 
 

2008-2009

PDF - 477 KB

2R44AI068543

Diagnostics

Diagnostics, Point-of-care testing, Infectious diseases, HIV, Hepatitis

 

MD Informatics, LLC

 
 
 
 

2009-2010

PDF - 53 KB

2 R44 NR010179-02

Healthcare IT, Continuing Medical Education

Continuing Medical education, computer-based tools, Healthcare IT, technological innovation, case-based learning

 

MediSpin Inc.

 
 
 
 

2009-2010

PDF - 217 KB

HHS-N-271-2009-00033C

Medical Communications & Information Technology

ADHD, Communicatio, Software, Evidence-based, Monitor

 

Medsright Getting It Right!

 
 
 
 

2008-2009

PDF - 317 KB

2R44 HD044353-02A2

Medical/Healthcare IT and Education

error, medication, nurses, software, training

 

Metabolic Nutritionals

 
 
 
 

2009-2010

PDF - 422 KB

1R43 HD-38234

Medical Innovations

Infant Feeding, Feeding Assessment, Infant Screening, Feeding Readiness, Neurodevelopmental Diagnosis

 

MetaMedia Training International, Inc.

 
 
 
 

2009-2010

PDF - 66 KB

2R44ES014762-02

Occupational Health and Safety; Disaster Response; HAZMAT; Building Engineer (Facilities Management)

Multimedia interactive training, safety, emergency response, incident command, HAZMAT

 

Micron Optics

 
 
 
 

2007-2008

PDF - 131 KB

5R44CA107782-03

Bio-Medical Imaging

Swept Laser, Optical Coherence Tomography, Tissue Imaging, Molecular Imaging, Optical Frequency Domain Ranging

 

MicroProbes for Life Science

 
 
 
 

2009-2010

PDF - 67 KB

2 R44 NS051036-02A2

Life Science Research/Medical Devices

Microelectrodes, multi-channel array, neuroscience, implant, research

 

MicroSurfaces

 
 
 
 

2007-2008

PDF - 164 KB

2R44RR017130-02

Biochips, biosensors, and bioanalytical instrumentation

microarrays, biosensors, immobilizationsingle molecule, membrane proteins

 

Mimosa Acoustics

 
 
 
 

2007-2008

PDF - 160 KB

5R44 DC006554

Audiological Medical Devices

audiology, hearing, middle ear, diagnosis, medical device

 

Mind Matters Research

 
 
 
 

2008-2009

PDF - 68 KB

2 R44 CA117597-02A2

Medical rehabilitation

Breast Cancer; Post-treatment intervention; Stress reduction; Chemobrain; Cancer fatigue

 

MMJ Labs LLC

 
 
 
 

2009-2010

PDF - 81 KB

1 R44 HD056647-01A2

Medical Devices

needle pain relief, immunizations, shots, vaccination, pain management

 

Molecular Design International

 
 
 
 

2007-2008

PDF - 95 KB

5R44AR049621

Pharmaceuticals

obesity, diabetes

 

Myomics, Inc.

 
 
 
 

2009-2010

PDF - 116 KB

2 R44 NS059098-02

High Content Drug Screening

Drug screening, skeletal muscle, muscular dystrophy, cardiovascular, sports medicine

 

Najit Technologies, Inc.

 
 
 
 

2011-2012

PDF - 49 KB

R44AI079898

Vaccine Market

vaccine manufacturing; emerging and re-emerging infectious disease; military and traveler's market; yellow fever; dengue hemorrhagic fever

 

NanoMedex Pharmaceuticals, Inc.

 
 
 
 

2008-2009

PDF - 241 KB

5R44GM072142-03

Pharmaceuticals

pharmaceuticals, propofol, microemulsion,injectables, reformulation

 

Nanoprobes, Inc.

 
 
 
 

2008-2009

PDF - 289 KB

5R44CA108013-03

Biotechnology, Nanotechnology, Nanomedicine, Contrast Agents, Cancer Imaging and Cancer Therapy

Gold, nanoparticles, colonoscopy, colon cancer, virtual colonoscopy

 

Nanotherapeutics

 
 
 
 

2007-2008

PDF - 144 KB

HHSN271200577414C

Pharmaceutical and Biologics

Opiate abuse, Buprenorphine, Oral Delivery, Bioavailability, Particle Dispersion

 

Neuro Kinetics, Inc.

 
 
 
 

2011-2012

PDF - 105 KB

2R44NS67772-02

Medical Devices

Diabetes, Retinopathy, I-Portal, Diagnostic, Ophthalmology

 

Neurobiotex, Inc.

 
 
 
 

2009-2010

PDF - 108 KB

2R44CA096354-02A2

Medical Devices and Diagnostics

prostate disease, Ionic zinc signal, brain disorders, cancer, metabolic biomarkers

 

NeuroDx Development

 
 
 
 

2011-2012

PDF - 73 KB

2R44EY018025-02

Diagnostic Medical Devices

Hydrocephalus, CSF Shunts, Intracranial Pressure (ICP), Neurosurgery, Diagnostic Medical Devices

 

NeurOp

 
 
 
 

2011-2012

PDF - 79 KB

1 U44 NS071657-01A1

Biopharmaceuticals

cerebral ischemia, depression, neuropathic pain, schizophrenia, NMDAR subunits

 

Northwest Media, Inc

 
 
 
 

2009-2010

PDF - 80 KB

5R44 HD041335-03

Social learning products

Online training, Foster parents, Parenting education, Social learning, Behavior management

 

Novaflux

 
 
 
 

2007-2008

PDF - 104 KB

5R44DK055419-05

Medical devices, reprocessing, dialysis, endoscopy

Hemodialysis, Dialyzer reuse, Hemodialyzer reprocessing, Dialyzer membrane cleaning, Cleaning

 

Omicia

 
 
 
 

2007-2008

PDF - 143 KB

1R44HG002993-02A1

Life Sciences

Molecular diagnostics, Genetic risk assessment, Personalized medicine, Disease gene bioinformatics platform, Genomic medicine

 

Omneuron

 
 
 
 

2007-2008

PDF - 102 KB

2R44NS050642-06

Medical Devices

chronic pain, addiction, neuroimaging, real-time, functional MRI

 

Optimum Therapeutics, LLC

 
 
 
 

2008-2009

PDF - 96 KB

R44CA103133

Oncology Therapeutics and Drug Delivery

cancer, therapeutics, delivery, peritoneal, pancreatic

 

Oxford Biomedical Research

 
 
 
 

2007-2008

PDF - 111 KB

5R44-ES-12277

Tools for biomedical research & human wellness assessment

Oxidative stress, Nutraceutical Efficacy, Wellness assessment, Inflammation, Biomarkers

 

Packet Digital LLC

 
 
 
 

2011-2012

PDF - 905 KB

4R44DC011231-02

Power management integrated circuits for electronics in medical devices, consumer and defense industries

Power Management, Extended Battery Life, Hearing Aids, On-Demand Power technology, dynamic voltage scaling

 

Parallel Synthesis Technologies, Inc.

 
 
 
 

2008-2009

PDF - 54 KB

5R44HG003911-03

Biotechnology, Diagnostic Tools

Multiplex, Diagnostic, Bead-based, Optical Encoding, Parallume

 

Pathfinder Therapeutics, Inc.

 
 
 
 

2008-2009

PDF - 120 KB

5R44CA119502-03

Medical Devices

imaging, surgery, medical device, cancer

 

Perinatronics Medical Systems, Inc.

 
 
 
 

2007-2008

PDF - 112 KB

2R44 HL 66791

Medical Devices

MRI, ECG, trigger, cardiovascular, scanner

 

PGXL Laboratories, LLC

 
 
 
 

2008-2009

PDF - 260 KB

2R44 HL090055-02

Personalized Medicine/Clinical Laboratory Diagnostics

Personalized Medicine, Pharmacogenetics, Pharmacogenomics, Anticoagulation, Warfarin

 

Pharm I.R., Inc.

 
 
 
 

2008-2009

PDF - 394 KB

5R44RR021232-03

Health care, health information technology

medication error, drug name confusion, patient safety, health information technology

 

PharmaIN, Corp.

 
 
 
 

2009-2010

PDF - 157 KB

5R44DK069727-05

Pharmaceuticals

Drug Delivery, Peptides, Proteins, Diabetes, Cancer

 

Photon Migration

 
 
 
 

2007-2008

PDF - 131 KB

2R44NS049734-02

Medical Imaging Systems

Medical Imaging Systems

 

Physical Sciences Inc.

 
 
 
 

2008-2009

PDF - 122 KB

2R44HL086809-03

High Content Instrumentation for Drug Discovery

predictive toxicology, arrhythmia, cardiac, zebrafish, Doppler

 

PICS

 
 
 
 

2007-2008

PDF - 122 KB

N44CN35152

Software

eDiaries, EDC, ePRO, PRO, Clinical Trials

 

Polyglot Systems, Inc.

 
 
 
 

2008-2009

PDF - 170 KB

5R44MD001212-03

Efficiency Improvement and Disparity Reduction

pharmacy, language, LEP, medication, safety

 

Potomac Affinity Proteins

 
 
 
 

2007-2008

PDF - 142 KB

2R44GM076786-02

Biotechnology

protein, purification, tag, affinity, recombinant

 

Powerscope

 
 
 
 

2007-2008

PDF - 114 KB

2R44HL081789-02

Medical Devices and Optical Instrumentation

inhalation therapy, drug delivery, aerosol, lung

 

Prairie Technologies

 
 
 
 

2011-2012

PDF - 56 KB

2R44MH065724-04A2

Biological research (laser microscopy)

microscopy, confocal, neuroscience, cell biology, imaging

 

Precision Bioassay

 
 
 
 

2007-2008

PDF - 104 KB

2R44RR021296-02

Analytic services supporting quality control of pharmaceutical biotechnology products

Bioassay, statistics, laboratory robotics, biological assay, validation

 

Protein Discovery

 
 
 
 

2007-2008

PDF - 166 KB

2R44RR022662-2

Life Sciences

Life Sciences, human plasma

 

Psychology Software Tools, Inc.

 
 
 
 

2008-2009

PDF - 155 KB

5R44AG022792

Assessment

Cognitive,Screen, Dementia, Assessment Computer,

 

Quantum Tubers Corporation

 
 
 
 

2008-2009

PDF - 52 KB

2R44HL083553-02

Biopharmaceutical

Plant-derived Vaccine, Biomanufacturing, Plant Biomass

 

Quest Product Development Corp

 
 
 
 

2008-2009

PDF - 107 KB

2R44HL080826-03A1

Product Development, Medical Devices, Engineering Services for Life Sciences

resuscitation, CPR, cardiac synchronization, cardiac arrest

 

Real-Time Tomography, LLC

 
 
 
 

2008-2009

PDF - 272 KB

1R44EB07140-01

Medical Devices

Breast Cancer, Medical imaging, image processing, real-time, tomosynthesis

 

Recombinant Technologies

 
 
 
 

2009-2010

PDF - 71 KB

2R44AG023457

Biotechnology/Pharmaceutical

Alzheimer's drug, neuroprotective agent, small molecule drug for AD, Amytrap, Alzheimer's therapeutic

 

Reprogenetics

 
 
 
 

2009-2010

PDF - 73 KB

1-R44-HD44313-02

Biotechnology - Diagnostics

genetic counseling, embryo biopsy, cell fixation, single gene disorders

 

Samuels & Associates

 
 
 
 

2009-2010

PDF - 83 KB

2R44DK078457-02

Public Health Research and Evaluation

Health disparities, childhood obesity, nutrition policy, nutrition, software tool

 

SANARIA

 
 
 
 

2007-2008

PDF - 98 KB

5R44AI055229-05

Biotechnology (Vaccines)

malaria, vaccine

 

Santech, Inc.

 
 
 
 

2009-2010

PDF - 58 KB

R44 HD 048991

Technology-Assisted Weight Loss and Health Behavior Change Programs

Weight loss, Obesity, Mothers, Internet, SMS

 

Science Learning Resources

 
 
 
 

2011-2012

PDF - 86 KB

5R44AA018245-03

Science Education Software and Curriculum Development

Science Education Software, Fetal Alcohol Spectrum Disorders (FASD), virtual microscopy, Curriculum Development, An Ounce of Prevention

 

SciTech Development

 
 
 
 

2007-2008

PDF - 133 KB

5R44CA093115-3

Oncology Drug Development and Delivery

oncology, pancreas, Fenretinide, drug delivery, bioavailibility

 

sComm

 
 
 
 

2007-2008

PDF - 105 KB

5R44 DC005881-03

Healthcare

healthcare, communication, deaf, UbiDuo, face-to-face

 

Senex Biotechnology, Inc.

 
 
 
 

2009-2010

PDF - 55 KB

R44 CA139991

Pharmaceuticals

Cancer, Alzheimer's, HIV, small molecule, potential near-term liquidity event

 

Sharklet Technologies, Inc.

 
 
 
 

2011-2012

PDF - 94 KB

2R44DK84590-02

Medical Devices

Surface modification, surface technology, micro-topography, No-Kill or non-toxic, Revolutionary, Bacterial inhibition, HAI or CAUTI prevention/reduction

 

Silver Lake Research Corporation

 
 
 
 

2011-2012

PDF - 45 KB

2R44DK085767-02

Diagnostics

Clinical diagnostics, urinary tract infection, UTI, infectious disease testing, lateral flow assay, EAP System

 

SimQuest

 
 
 
 

2009-2010

PDF - 46 KB

4R44EB008604-02

Technology-assisted healthcare training

surgical simulation, open surgery, surgical simulator, surgical training, and surgery

 

SonarMed, Inc.

 
 
 
 

2008-2009

PDF - 92 KB

2R44HL080796-04A1

Medical Devices, Class II, Respiratory Care/Airway Management

Endotracheal Tube Monitoring, Respiratory Care

 

SonoGene LLC

 
 
 
 

2011-2012

PDF - 144 KB

HL 095238-01

Biotechnology / Pharmaceutical

gene therapy, contrast ultrasound, HDL, choelsterol, contrast-enhanced, ultrasound (CEUS)

 

Source Production & Equipment Co., Inc.

 
 
 
 

2009-2010

PDF - 70 KB

2R44CA125999-03

Medical Devices

brachytherapy, cancer, lung, wedge-resection, VATS

 

Stoecker & Associates

 
 
 
 

2011-2012

PDF - 122 KB

2R44CA-101639-02A2

Medical Diagnostics, Software Device

malignant melanoma diagnosis, improved recognition, Automatic detection, low price, Melanoscan

 

Strategic Polymer Sciences, Inc.

 
 
 
 

2009-2010

PDF - 131 KB

12R44HL091582-02

Medical Devices

electroactive polymer, high energy density capacitor, pulsed power, polymer film, medical devices

 

Super Pulse

 
 
 
 

2011-2012

PDF - 83 KB

R44 DE017831-03

Medical Devices

Room Temperature Sterilization, Free Radicals, Non-Thermal Plasma, Decontamination, Disinfection

 

SVision LLC

 
 
 
 

2007-2008

PDF - 115 KB

2R44MH075498-02A1

Life science instrumentation

Software, Machine learning, Microscopy imaging analysis, Microscopy data analysis,image based clinical diagnostic

 

Synedgen

 
 
 
 

2011-2012

PDF - 322 KB

2R44DE019740-02

Biotech/pharma

Oral mucositis treatment, sinusitis treatment, burn and wound infection prophylactic, polysaccharide derivatives, prevent infection

 

Tanglewood Research

 
 
 
 

2007-2008

PDF - 135 KB

N44DA-2-5509

Software

online data collection, health education

 

Targeson, Inc.

 
 
 
 

2011-2012

PDF - 139 KB

2R44EB007857-02

Health care: In vivo diagnostics

ultrasound-based molecular imaging agents, In vivo diagnostics, angiogenesis targeted imaging agents, pharmaceutical research, Academic research

 

TDA Research

 
 
 
 

2007-2008

PDF - 100 KB

2R44GM076754-02

Pharmaceutical Manufacturing

Catalysis, Asymmetric, Hydrogenation, Continuous, Ruthenium, Pharmaceuticals

 

Techniscan Medical

 
 
 
 

2007-2008

PDF - 100 KB

4R44CA110203-02

Medical devices

UltraSound, imaging

 

TechnoVax, Inc.

 
 
 
 

2009-2010

PDF - 303 KB

2R44 AI063830-03A1

Biotech Vaccine Discovery and Development

Virus-like particle (VLP) technology, vaccines, influenza, respiratory syncytial virus (RSV), Dengue

 

Tesla Laboratories, Inc.

 
 
 
 

2008-2009

PDF - 69 KB

2R44ES013622 - 02

Environmental Remediation, Toxin Mitigation, Recycling

Water treatment, metal recovery, advanced electrowinning, waste reclamation, waster conversion, toxin mitigation

 

Therapeutic Systems Research Laboratories, Inc.

 
 
 
 

2011-2012

PDF - 125 KB

2R44AI081396-02

Pharmaceuticals

biopharmaceuticals, oral delivery, endogenous intestinal transporters, antiviral and anti-cancer therapeutics, enhanced absorption

 

TheraSource LLC

 
 
 
 

2008-2009

PDF - 44 KB

2R44GM073249-02A1

Biopharmaceuticals

Sepsis, Bowel Ischemia, Critical Care, Peptides, Therapeutics

 

Third Dimension Technologies

 
 
 
 

2011-2012

PDF - 146 KB

2R44EB004221-02

Training Simulation, Diagnostic Imaging, Drug Discovery, Telepresence Geo-spatial Intelligence, Oil & Gas Exploration, Computer Aided Design

Angular Slice 3D, stereopsis, Diagnostic Imaging, Computer Aided Design, real world

 

Touch of Life Technologies

 
 
 
 

2008-2009

PDF - 76 KB

2 R44 AR049637-02

Health Care Education

health care education, haptic display, virtual reality, Medical Procedure simulators, virtual anatomy

 

Transcendent International LLC (dba LanguageMate)

 
 
 
 

2009-2010

PDF - 107 KB

2R44GM080836-02

Healthcare Informatics

prosthesis, foot, tensegrity, prosthetic, amputee

 

Transposagen Biopharmaceuticals, Inc.

 
 
 
 

2008-2009

PDF - 92 KB

2R44RR021289-02A1

Research Tools - Genetically Modified Research Animal Models

knockout rat, animal model, transgenic rat, aboratory rat, gene knockout, toxicology rat, disease model

 

Transtimulation Research

 
 
 
 

2007-2008

PDF - 103 KB

DK063733

Medical devices

electrical stimulation therapies

 

Triple Ring Technologies

 
 
 
 

2011-2012

PDF - 50 KB

1R44RR031964-01

Medical Devices, Homeland Security

X-ray imaging, scatter rejection, region-based exposure control, biomedical imaging, X-ray imaging capabilities beyond traditional 2D shadowgrams

 

TSRL

 
 
 
 

2007-2008

PDF - 118 KB

2R44AI056864-03A1

Pharmaceuticals

Oral drug delivery, Antiviral therapy, Prodrug technology, Biodefenseanti-cancer therapy

 

Urovalve

 
 
 
 

2007-2008

PDF - 161 KB

2R44HD039566-02A1

Medical devices

Medical Device, Urology, New Jersey

 

Vida Health Communications, Inc.

 
 
 
 

2009-2010

PDF - 112 KB

2R44HD042313-02

Health Media

Public health, media, prevention , intervention, professional development, interactive learning, award-winning

 

Virtual Reality Medical Center

 
 
 
 

2007-2008

PDF - 112 KB

4 R44 DA022100-02

Healthcare

virtual reality, optical

 

VisionQuest Biomedical, LLC

 
 
 
 

2009-2010

PDF - 53 KB

EY018280

Medical Devices and Service

retina, optic disc, eye diseases, affordable eye care

 

Vitatex

 
 
 
 

2011-2012

PDF - 82 KB

5R44CA140047-03

Clinical Diagnostics and Biomedical Research Products

cancer diagnostics, circulating tumor cell, metastasis, drug response testing, rare blood cells

 

Vivo Biosciences Inc.

 
 
 
 

2008-2009

PDF - 97 KB

2R44CA108118-04

Life Sciences Biotechnology

Preclinical testing, Human bioassay, Therapy prediction, 3D Tumor model and Drug screening

 

VPDiagnostics

 
 
 
 

2007-2008

PDF - 107 KB

2 R44 HL70576-04A1

Medical devices

Stroke, Assessment, Carotid, Vessel, MRI

 

Wave 80 Biosciences

 
 
 
 

2009-2010

PDF - 53 KB

2R44AI073221-02

Molecular Diagnostics

Molecular Diagnostics, Medical Device, HIV AIDS Hepatitis, Biotech, Infectious Disease

 

Women Insight, Inc. (Bodimojo)

 
 
 
 

2009-2010

PDF - 69 KB

2R44 DK074280-02A1

Online Health Media

adolescents, web-based, behavior change, health promotion, obesity prevention

 

X-Ray Optical Systems, Inc.

 
 
 
 

2008-2009

PDF - 319 KB

5 R44 RR021797-03

Material analysis, optics and instrument production

Trace element analysis, ICP-MS, atomic absorption spectroscopy, body fluids, x-ray fluorescence

 

Xemed LLC

 
 
 
 

2008-2009

PDF - 55 KB

2R44HL087550

Diagnostics

Hyperpolarized 129Xenon, 3He, pulmonary functional MRI, COPD, asthma

 

Xhale, Inc.

 
 
 
 

2009-2010

PDF - 129 KB

2R44MH081767-02A1

Medical Devices and Pharmaceuticals

Drug compliance, Patient management, medication adherence monitoring, therapeutic drug monitoring, drug counterfeiting

 

Ximerex

 
 
 
 

2007-2008

PDF - 111 KB

R44DK057986

Biotechnology – Regenerative Medicine/Transplantation

Transplantation, Regenerative Medicine, Diabetes, Humanized, PERV

 

XL Sci-Tech

 
 
 
 

2007-2008

PDF - 150 KB

2R44CA121641--02

Medical Devices for treatment of soft tissue cancers

Timed bioabsorbable,Brachytherapy seeds, Radioisotope encapsulation

 

Zumatek Inc.

 
 
 
 

2009-2010

PDF - 88 KB

2R44CA125924-02

Medical Devices

Breast imaging, Breast cancer, Mammography, Breast CT, Breast screening

 

Zylon

 
 
 
 

2007-2008

PDF - 105 KB

2R44-HL68331-02A2

Medical devices

angioplasty, balloon catheter, vascular diseases

 
Show More Results IconShow Less Results IconShow AllHide